Fact-checked by Grok 2 weeks ago

Human enhancement


Human enhancement encompasses biomedical, technological, and interventions aimed at augmenting human physical, cognitive, sensory, or psychological capacities beyond species-typical functioning, distinguishing it from therapies that merely restore . These efforts include pharmacological agents like nootropics for , cybernetic devices such as brain-computer interfaces for enhanced control, and genetic editing to confer heritable traits like disease resistance or heightened .
Historically rooted in rudimentary tools and , modern human enhancement leverages advances in and , with empirical demonstrations including exoskeletons that multiply human strength for industrial or applications and transcranial techniques yielding temporary boosts in learning . Proponents emphasize causal benefits such as extended healthy lifespan and mitigated evolutionary constraints, supported by data from trials showing targeted physiological improvements. However, realization often confronts physiological trade-offs, as genetic modifications can induce pleiotropic effects altering unrelated traits, underscoring the complexity of intervening in evolved biological systems. Controversies center on ethical boundaries, potential exacerbation of social inequalities through access disparities, and risks of like reduced population-level adaptability, with debates intensified by the dual-use nature of technologies originally developed for medical restoration. Empirical assessments reveal modest, context-specific gains rather than transformative leaps, as seen in studies of cognitive enhancers where benefits diminish under real-world variability. Despite regulatory hurdles and public , ongoing research in areas like CRISPR-based editing signals accelerating pursuit, driven by first-principles recognition of human adaptability as a selectable amenable to directed optimization.

Definition and Conceptual Foundations

Core Definition and Scope

Human enhancement refers to biomedical, technological, or pharmacological interventions designed to augment human physical, cognitive, sensory, or other capacities beyond species-typical functioning or an individual's baseline performance, in the absence of pathology. This contrasts with therapeutic measures, which aim to restore normal function impaired by disease, injury, or deficiency, such as repairing a damaged organ to achieve average health standards rather than exceeding them. The distinction hinges on intent and outcome: therapy addresses deficits to reach adequacy, while enhancement seeks competitive or aspirational superiority, raising questions about defining "normal" as statistical averages within a population or evolutionary norms. The scope of human enhancement encompasses a of methods targeting diverse human traits, from muscular strength and endurance—via anabolic agents or exoskeletons—to intellectual faculties, such as memory and problem-solving enhanced by compounds or devices. Reproductive enhancements, including genetic selection for desired traits in offspring, and extensions through drugs or manipulation, also fall within this domain, though for widespread efficacy remains limited to preclinical or early-stage trials as of 2023. Moral or emotional enhancements, posited to involve interventions altering empathy or impulse control via or pharmaceuticals, represent more speculative frontiers, with philosophical debates centering on whether such changes constitute genuine improvement or mere preference satisfaction. Empirical boundaries of enhancement are informed by causal mechanisms: interventions must demonstrably exceed or training effects, as seen in studies where improves wakefulness in healthy subjects beyond caffeine's limits, yielding 10-20% gains in cognitive tasks under . Scope excludes non-invasive practices like or exercise, which optimize within genetic constraints, focusing instead on direct physiological or neural modifications. Debates persist on inclusivity, with some scholars arguing enhancements should prioritize metrics over raw , yet first-principles emphasizes measurable, heritable, or durable expansions verifiable through controlled trials.

Distinction from Therapy and Normalization

Therapeutic interventions, by definition, address pathologies or impairments to restore or preserve species-typical functioning, such as treating insulin deficiency in to normalize blood glucose levels or repairing damaged neural pathways post-stroke. Human enhancement, conversely, applies to non-therapeutic modifications of healthy individuals aimed at surpassing baseline human capacities, exemplified by drugs boosting cognitive performance in unimpaired users or genetic edits increasing muscle efficiency beyond natural variance. This demarcation hinges on causal intent: counters deviation below norms due to or , while enhancement proactively elevates traits irrespective of deficit. Normalization interventions occupy an intermediate conceptual space, targeting subnormal traits to align with statistical or functional averages without exceeding them, such as administering human growth hormone to children with idiopathic short stature to achieve average height rather than exceptional stature. Unlike enhancement, which aspires to competitive or aspirational superiority—e.g., CRISPR-based edits for heightened intelligence in normotypic embryos—normalization prioritizes conformity to established baselines, often justified under therapeutic rationales when deficits are mild or socially constructed. Empirical data from clinical trials underscore this: U.S. Food and Drug Administration approvals for growth hormone expanded in 2003 to include non-pathological short stature, framing it as normalization, yet ethicists debate whether repeated such expansions erode enhancement boundaries by iteratively redefining "normal." Critics, including bioethicists and , contend the therapy-enhancement-normalization trichotomy falters under scrutiny, as "normal" lacks fixed empirical anchors—statistical medians shift with interventions, and functional norms vary by context (e.g., vaccinating against diseases enhances immunity beyond pre-epidemic baselines, blurring preventive therapy into enhancement). Causal realism reveals these categories as pragmatic heuristics rather than ontological absolutes: enhancements can normalize if adopted widely, as prosthetic limbs did for amputees, transitioning from restorative aids to capability extenders. Regulatory bodies like the maintain the divide for oversight, fast-tracking therapies for unmet medical needs while imposing stringent safety thresholds on enhancements absent therapeutic justification, evidenced by the 2018 rejection of non-medical gene-editing proposals amid equity concerns. Despite fluidity, the distinction informs policy, with enhancement facing higher evidentiary bars due to risks like unintended off-target effects in edits, documented in 2018 trials where purported enhancements yielded mosaicism and unknown long-term harms.

Historical Development

Ancient and Pre-Modern Practices

In , efforts to enhance physical performance centered on athletic training for the , which began in 776 BCE and emphasized disciplines such as running, wrestling, and . Competitors followed rigorous regimens involving with weights, sprints, and combat simulations, often under professional trainers (paidotribai) who optimized techniques for strength and endurance. Diets were high in , particularly and , to promote muscle growth, contrasting with the broader population's grain-based intake, as documented in accounts by (c. 129–216 CE). Pharmacological aids supplemented these practices, with athletes consuming potions derived from herbs, hallucinogens, strychnine, and to boost alertness, reduce pain, or induce euphoria during competition. Specially prepared meats and animal organs, such as boar's testicles, were ingested for purported vitality transfer, reflecting early beliefs in for performance gains. These methods, while effective for short-term edges in isolated cases, carried risks like toxicity, as convulsions could mimic or exacerbate exertion-related injuries. In ancient , Ayurveda's Rasayana branch, codified in texts like the (c. 300 BCE–200 CE), targeted holistic enhancement through rejuvenative therapies promoting , immunity, and cognitive acuity. Rasayana protocols involved herbal decoctions from plants like Emblica officinalis (amalaki) and (ashwagandha), which provided and adaptogenic effects to nourish dhatus (tissues) and amplify ojas (vital essence). These were administered after detoxification (shodhana) to optimize absorption, yielding reported benefits in and disease resistance, though empirical validation relies on traditional pharmacopeia rather than controlled trials. Parallel developments in Traditional Chinese Medicine (TCM), as outlined in the Huangdi Neijing (c. 200 BCE), employed tonics to augment qi (vital energy) and extend lifespan. Herbs such as Panax ginseng and Ephedra sinica were used to enhance stamina and respiratory efficiency, with ginseng's ginsenosides supporting metabolic resilience in historical formulations. Emperors like Qin Shi Huang (r. 221–210 BCE) pursued alchemical elixirs (waidan) blending mercury and cinnabar for immortality, though these often proved lethal due to heavy metal toxicity rather than true enhancement. Internal alchemy (neidan) later emphasized meditative and respiratory practices for subtle physiological refinement, predating modern biofeedback. Pre-modern European practices extended these traditions into monastic and alchemical pursuits, such as medieval quests for life-extending elixirs via of herbs and minerals, aiming to transcend natural decay. These efforts, while speculative, laid groundwork for empirical by isolating active compounds, albeit with inconsistent outcomes due to rudimentary understanding of . Across cultures, such interventions prioritized empirical observation of outcomes—like sustained vigor in users—over theoretical purity, highlighting causal links between regimen adherence and amplified capacities.

20th Century Foundations

The movement, originating in the late 19th century but peaking in implementation during the early 20th, constituted an initial organized attempt to enhance human genetic stock through selective reproduction and intervention. Proponents, drawing on Darwinian principles, advocated policies to increase desirable traits and reduce hereditary "defects," including , restrictions, and sterilization of individuals classified as , criminal, or otherwise unfit. , thirty-two states enacted laws by the 1930s, resulting in approximately 70,000 procedures from 1907 to the 1970s, often applied disproportionately to the poor, immigrants, and racial minorities without . Upheld by the in (1927), which justified sterilizing "imbeciles" to prevent societal burdens, these programs reflected a causal in as the primary driver of human quality, though empirical validation was limited and often pseudoscientific. The movement's extremes, particularly Nazi Germany's program that sterilized or euthanized over 400,000 by 1945, exposed its coercive risks and ethical failures, leading to international repudiation after via documents like the 1948 . Despite discreditation, eugenics influenced later genetic enhancement discussions by establishing population-level intervention as a paradigm, albeit shifting toward voluntary methods post-1945. Pharmacological approaches provided another 20th-century avenue for individual enhancement, focusing on chemical modulation of and . Amphetamines, synthesized in and commercialized in , were deployed for performance boosts, with widespread military adoption during —U.S. forces distributed over 200 million benzedrine tablets to soldiers for sustained alertness and reduced fatigue in combat. Anabolic-androgenic steroids, first isolated and synthesized in 1935 by chemists and Leopold Ruzicka, enabled beyond natural limits; by the 1950s, Eastern Bloc athletes systematically used testosterone derivatives, as evidenced by Soviet weightlifters dominating the 1952 Helsinki Olympics, prompting Western adoption despite health risks like liver damage and hormonal disruption. These substances demonstrated causal efficacy in enhancing physical endurance and strength—steroids increase protein synthesis by up to 200% in controlled studies—but raised concerns over dependency and unintended effects, foreshadowing regulatory battles like the U.S. Anabolic Steroids Control Act of 1990. Early nootropics, such as developed in 1964, targeted cognitive gains by improving cerebral metabolism, though evidence for broad enhancement remained anecdotal until later trials. Mid-century theoretical advances in and philosophy further solidified enhancement foundations by bridging biological and technological domains. Norbert Wiener's 1948 publication Cybernetics: Or Control and Communication in the Animal and the Machine formalized feedback loops governing human-machine interactions, enabling designs for adaptive prosthetics and servomechanisms that augmented impaired functions toward supernormal performance, as seen in early powered exoskeletons prototyped by the U.S. military in the 1960s. This interdisciplinary field emphasized empirical over , influencing enhancements like the first successful heart implant in 1958, which extended viability beyond natural cardiac limits. Concurrently, Julian Huxley's 1957 essay "" articulated a positive vision of enhancement, defining it as humanity's conscious transcendence of biological constraints via , education, and technology to achieve "evolutionary ." Huxley, a biologist and eugenics advocate, rejected coercive state measures in favor of individual and societal self-directed progress, stating: "The human species can, if it wishes, transcend itself—not just sporadically... but in its entirety, as humanity." These ideas, rooted in observable technological trajectories like and rocketry, provided causal to enhancement by prioritizing verifiable scientific mechanisms over speculative ideals, setting the stage for 21st-century integrations.

21st Century Acceleration and Key Milestones

The completion of the in April 2003 marked a pivotal acceleration in human enhancement by providing a comprehensive reference sequence of human DNA, enabling precise genetic interventions and approaches that extend beyond therapy to potential augmentation. This foundational data spurred investments in , with subsequent technologies like induced pluripotent stem cells (iPSCs), reprogrammed from adult cells in 2006 by Shinya Yamanaka's team, allowing for scalable and creation to enhance regenerative capacities. A major breakthrough occurred in 2012 with the adaptation of -Cas9 as a programmable gene-editing tool by and , revolutionizing precise DNA modifications for traits like disease resistance or metabolic efficiency, though initial applications focused on research models before human trials. By 2018, Chinese scientist announced the birth of twin girls edited with to confer resistance via mutation, demonstrating enhancement feasibility despite ethical backlash and his subsequent imprisonment, highlighting regulatory tensions in enhancement pursuits. Clinical translation advanced with the first in vivo trial in 2021 for , a form of blindness, using EDIT-101 to edit retinal cells, yielding partial vision restoration in participants by 2023. In cybernetic domains, DARPA's Revolutionizing Prosthetics program, initiated in 2006, yielded the DEKA Arm in 2007—a modular prosthetic with multiple controlled via neural signals—culminating in FDA approval for civilian use in 2014, surpassing natural limb dexterity in and for amputees. techniques, refined in the , enabled direct skeletal attachment of prosthetics, reducing socket-related complications and improving load-bearing, as evidenced by clinical trials showing enhanced stability in lower-limb users by 2015. Neural interfaces accelerated with DARPA's N3 program launched in 2018, funding nonsurgical bi-directional brain-machine interfaces using or for soldier augmentation, aiming for cognitive offloading without implantation. Neuralink's 2016 founding led to its first human implant in January 2024, with the N1 device enabling quadriplegic patients to control cursors and play games via thought by mid-2024; by mid-2025, three recipients demonstrated daily use for web browsing and 3D design, interfacing over 1,000 electrodes with bandwidth exceeding prior Utah arrays. These milestones reflect converging exponential gains in computation, , and , with private funding surpassing $500 million annually for BCIs by 2024, outpacing public efforts amid debates on dual-use enhancements.

Technological Categories

Pharmacological and Nootropic Methods

Pharmacological methods of human enhancement involve the use of synthetic or natural compounds to augment physical or cognitive capacities beyond baseline levels in healthy individuals. These include stimulants, hormones, and purported , often repurposed from therapeutic applications. Evidence for efficacy varies, with some agents demonstrating measurable improvements in controlled studies, while others show limited or context-dependent effects. Nootropics, a subset targeting cognitive enhancement, encompass drugs like and , which promote wakefulness and attention. A 2015 meta-analysis of 24 studies found improves cognitive performance in non-sleep-deprived healthy adults, particularly in such as planning, decision-making, and , with effect sizes indicating reliable but modest gains. 's mechanism involves increased and norepinephrine signaling in regions, enhancing task enjoyment and motivation without the euphoria of traditional stimulants. However, benefits are dose-dependent and more pronounced under fatigue, with long-term effects in healthy users unestablished due to sparse longitudinal data. Other nootropics, such as racetams (e.g., ) or natural compounds like and L-theanine, claim to boost and but yield inconsistent results in peer-reviewed trials. Systematic reviews indicate only marginal improvements in processing speed or executive function for multi-ingredient supplements, often failing to outperform in well-rested subjects. , studied for attention enhancement, shows gains in healthy individuals but primarily sustains performance during prolonged wakefulness rather than elevating peak capacity. For physical enhancement, anabolic-androgenic steroids (AAS) like testosterone derivatives increase muscle protein synthesis and . Clinical data from 1984 trials on weight-trained athletes confirm AAS elevate lean body mass by 2-5 kg and strength by 5-20% over 6-12 weeks, surpassing natural training limits via activation. Human growth hormone (hGH) and (EPO) further amplify recovery and oxygen delivery, with EPO raising levels by 10-15% to boost . These agents are widely used non-medically despite regulatory bans in sports, as their ergogenic effects stem from direct physiological modulation rather than mere caloric surplus. Overall, pharmacological enhancements offer targeted gains but require precise dosing to mitigate dependency risks, with empirical support strongest for in and AAS in musculature.

Genetic and Biological Interventions

Genetic interventions for human enhancement utilize technologies, such as CRISPR-Cas9, to make precise alterations to DNA sequences aimed at improving traits beyond baseline human capabilities. CRISPR-Cas9, derived from bacterial adaptive immune systems, functions by using a to direct the to specific genomic loci, enabling insertions, deletions, or replacements via the cell's mechanisms. While initially applied to model organisms, adaptations for human cells have facilitated potential enhancements in areas like disease resistance and physical performance; for instance, knockout of the gene in animals has resulted in doubled muscle mass without adverse effects on health. However, polygenic traits such as or involve thousands of genetic variants, complicating targeted enhancements and increasing risks of . Biological interventions extend to gene therapies, where vectors deliver modified s to non-reproductive cells, and , which reprograms cells for regenerative augmentation. Adeno-associated viruses (AAVs) and lentiviruses serve as common vectors for stable integration, with recent advancements improving delivery efficiency and reducing . In preclinical models, therapies genetically modified to overexpress angiogenic factors have enhanced vascularization and tissue repair beyond normal recovery, suggesting applications for superior or organ function. Induced pluripotent stem cells (iPSCs), reprogrammed from adult cells, can be edited via to incorporate enhancement alleles before differentiation into target tissues, though scalability and safety remain barriers. Human applications for enhancement remain nascent and largely prohibited by international guidelines, with documented cases limited to controversial germline edits. In 2018, Chinese researcher used to edit genes in human embryos, aiming for HIV resistance—a conferring potential advantages—but the procedure led to off-target mutations and global condemnation, resulting in his imprisonment. Somatic enhancements in adults, such as editing for enhanced muscle growth, lack approved clinical trials, as current trials focus on monogenic diseases like sickle cell anemia, where FDA-approved therapies like Casgevy restore function rather than augment it. Recent innovations, including AI-optimized guide RNAs and nanoparticle delivery, have tripled editing precision , but ethical concerns over , for heritable changes, and long-term mosaicism preclude widespread enhancement use. Empirical evidence from animal studies supports feasibility, yet human enhancement claims require rigorous validation to distinguish hype from causal efficacy.

Cybernetic and Prosthetic Augmentations

Cybernetic augmentations integrate electronic, mechanical, and systems with biological tissues to extend or modify human function, often through implantable or wearable devices that incorporate sensors and actuators for adaptation. Prosthetic augmentations, a , replace or supplement limbs and organs with artificial components designed for precise via neural or muscular signals. These technologies originated in restorative applications but have evolved toward enhancement, enabling capabilities such as increased strength, , and dexterity that exceed baseline human performance, particularly in demanding environments like military operations. A prominent example is the DEKA Arm System, commonly called the Luke Arm, developed through the U.S. Defense Advanced Research Projects Agency (DARPA) Revolutionizing Prosthetics program starting in 2006. This modular, battery-powered upper-limb prosthesis offers up to 10 powered joints, including a powered shoulder for overhead reach, and supports dexterous movements like simultaneous elbow flexion and hand grasping via electromyographic (EMG) signal processing. FDA-cleared in May 2014 for amputees, its pattern recognition software interprets multiple muscle signals for proportional control, achieving grip forces up to 20 pounds and speeds rivaling natural limbs in controlled tests. While primarily restorative, its advanced kinematics suggest potential for elective augmentation in healthy users to boost load-handling or precision tasks. Powered exoskeletons represent a non-invasive cybernetic approach, amplifying musculoskeletal output through hydraulic, pneumatic, or electric actuators synchronized with user intent. In military contexts, the U.S. Army has tested lower-body exoskeletons like the Human Universal Load Carrier (HULC), which reduces metabolic cost by 20% during load carriage exceeding 200 pounds over varied terrain, allowing soldiers to march longer without fatigue. The program, initiated by U.S. Command in 2013 with collaboration, aimed for a full-body enhancing strength by factors of 2-5 times natural limits, ballistic protection, and physiological monitoring; though the integrated suit was discontinued in 2019 due to integration challenges, it yielded prototypes improving endurance by offloading up to 100 pounds. These systems employ impedance control algorithms to adapt to , preventing unnatural strain. Advancements in sensory integration further blur restoration and enhancement boundaries. Bionic prostheses now incorporate haptic feedback via implanted electrodes stimulating residual nerves, restoring touch sensation with resolution detecting textures as fine as 1 mm in clinical trials as of 2023. algorithms in modern devices, such as those using neural network-based EMG decoding, enable adaptive control reducing user training time to under 10 hours and improving accuracy to 95% for multi-joint motions. For non-medical enhancement, industrial exoskeletons like those from Ekso Bionics have demonstrated 15-30% reductions in muscle exertion during repetitive lifting, potentially applicable to healthy workers or athletes for and performance extension. Empirical data from field trials indicate these augmentations can increase work output by 10-20% without compensatory biomechanical alterations, though long-term and power efficiency remain constraints.

Neural Interfaces and Brain-Computer Integration

Neural interfaces, also known as brain-computer interfaces (BCIs), facilitate direct interaction between the and external computational systems by detecting, interpreting, and modulating neural signals. These systems typically involve electrodes or sensors that record electrical activity from neurons or stimulate them to elicit responses, enabling bidirectional communication. Invasive BCIs, such as those using microelectrode arrays implanted in the , offer higher signal resolution and bandwidth compared to non-invasive methods like (EEG), which rely on scalp-based recordings but suffer from lower fidelity due to signal attenuation through skull and tissue. For human enhancement purposes, invasive approaches are prioritized for their potential to achieve precise, high-throughput data transfer, surpassing natural sensory-motor limitations, though current implementations remain constrained by and surgical risks. Pioneering efforts in enhancement-oriented BCIs include 's N1 implant, a coin-sized device with 1,024 electrodes on flexible polymer threads inserted via robotic surgery to minimize tissue damage. In 2021, Neuralink demonstrated a monkey controlling a computer cursor and playing solely through neural signals, establishing proof-of-concept for volitional control without physical movement. Human trials commenced in January 2024 with quadriplegic patient Noland Arbaugh, who achieved cursor navigation, digital interaction, and gaming at speeds approaching those of non-impaired individuals, with reported typing rates improving to over 8 words per minute by mid-2024. By September 2025, Neuralink had implanted devices in 12 participants, primarily targeting motor restoration but yielding data on sustained neural recording stability exceeding prior Utah benchmarks, with electrode counts enabling detection of up to 1,000+ individual neurons. Complementary technologies, such as Synchron's Stentrode—a stent-mounted deployed endovascularly—have enabled thought-based text composition in clinical settings since 2021, bypassing open-brain surgery while supporting wireless data transmission. Empirical evidence for enhancement beyond therapeutic restoration includes demonstrations of augmented control precision and speed in implanted subjects, where neural decoding algorithms process spike patterns in real-time to outperform manual interfaces in constrained scenarios. For instance, Neuralink's systems have facilitated telepathic-like operation of multiple devices simultaneously, hinting at scalability for cognitive offloading, such as direct symbiosis for accelerated . However, bandwidth remains a bottleneck—current invasive BCIs achieve throughputs of 10-100 bits per second, orders of magnitude below the brain's estimated 10^14 synaptic operations per second—limiting applications to commands rather than seamless perceptual integration. Ongoing advancements, including FDA designation for Neuralink's vision-restoring implant in September 2024, underscore progress toward sensory augmentation, though full enhancement paradigms like memory or skill acquisition via neural stimulation await validation in non-clinical cohorts. Peer-reviewed analyses emphasize that while therapeutic biases dominate funding and trials, the underlying signal-processing frameworks inherently support transhumanist extensions, contingent on resolving and signal drift.

Emerging Speculative Approaches

Whole brain emulation (WBE), also known as , proposes scanning the human brain at the synaptic or connectomic level to create a digital simulation of and on a computational substrate. This approach aims to enable indefinite substrate-independent existence, potentially overcoming biological mortality and allowing scalable cognitive enhancements such as or integration with artificial . Theoretical roadmaps, such as those outlined by and in 2008, identify key prerequisites including non-destructive high-resolution brain scanning (e.g., via advanced electron microscopy or nanoscale imaging) and capable of simulating 10^14 to 10^17 neural operations per second, with projections suggesting feasibility within decades if scanning and emulation technologies advance exponentially. However, empirical progress remains limited to partial worm emulations as of 2014, with human-scale challenges including preserving dynamic biochemical states and ensuring behavioral fidelity beyond static structure. Molecular nanotechnology, envisioning programmable self-replicating molecular assemblers, offers speculative pathways for atom-precise reconfiguration of human tissues, enabling enhancements like ubiquitous cellular repair, custom , or integration of novel biomaterials for superior strength and resilience. Eric Drexler's foundational concepts from the 1980s posit "nanofactories" capable of building macroscopic structures from atomic feedstocks, potentially revolutionizing enhancement by allowing reversible morphological changes without surgical intervention. Recent discussions highlight applications in or neural rewiring, but realization hinges on overcoming quantum-scale fabrication barriers, with current limited to passive nanostructures like carbon nanotubes rather than active assemblers. Ethical analyses critique the field's speculative ethics, noting risks of uncontrolled replication (the "" scenario) while emphasizing the need for empirical validation through incremental prototypes. Other nascent ideas include synthetic biology-driven chimeras, merging neural tissue with engineered organisms for hybrid cognition, or quantum-enhanced neural interfaces leveraging hypothetical brain-quantum computing hybrids for probabilistic reasoning beyond classical limits. These remain conceptual, with no verified prototypes as of 2025, grounded in extrapolations from current and quantum sensing research. Proponents argue such integrations could yield adaptability, as explored in transhumanist frameworks aiming for "super " via iterative biological redesign. Skeptics, drawing from evolutionary , caution that radical departures from organic substrates may disrupt emergent , underscoring the absence of causal evidence linking digital or nano-scale proxies to preserved .

Empirical Benefits and Evidence

Physical Performance and Resilience Gains

Anabolic-androgenic steroids (AAS) have demonstrated measurable improvements in muscle strength and in controlled studies of trained individuals. A review of performance-enhancing drugs indicated that AAS usage results in strength gains ranging from 5% to 52%, alongside a standardized mean difference of 0.62 in , though accompanied by disruptions. Supraphysiologic doses of testosterone, particularly when paired with resistance training, increase fat-free mass, muscle size, and strength in healthy men, with dose-dependent effects observed in trials administering 25 to 600 mg weekly. Genetic interventions targeting , a negative regulator of muscle growth, show promise for enhancing physical performance based on preclinical data. In animal models, myostatin inhibition via vectors like AAV1 has yielded 30-50% increases in mass and , with reduced serum markers of muscle damage. Monoclonal antibodies blocking myostatin have enhanced muscle mass and function in both young and aged mice, suggesting potential for without proportional gains in force production in some fiber types. Human clinical trials of myostatin inhibitors, primarily for muscular dystrophies, have aimed to boost muscular function since the early 2000s, but direct applications to healthy enhancement remain exploratory and unapproved, with animal studies informing ergogenic possibilities. Cybernetic augmentations, such as powered exoskeletons, augment load-carrying capacity and reduce metabolic demands in contexts, thereby enhancing and to . Studies indicate exoskeletons diminish physical and risk during repetitive tasks, with prototypes enabling soldiers to carry heavier loads over extended periods without proportional increases in expenditure. However, limitations and ergonomic challenges persist, limiting widespread deployment as of 2025. Prosthetic lower-limb devices enable competitive athletic participation for amputees, though biomechanical analyses reveal no consistent superiority over biological limbs in events like 400 m sprints. Prostheses return approximately 90% of stride energy, compared to up to 240% from intact human legs and feet, resulting in lower ground reaction forces and potential disadvantages at certain speeds. Elite performers with below-knee prostheses approach able-bodied distances through optimized asymmetry in spring-force mechanics, but overall records reflect adaptations rather than inherent advantages. Stem cell therapies contribute to by accelerating recovery from musculoskeletal injuries, a common limiter of . Clinical case series report improved healing of traumatic muscle injuries, with mesenchymal s promoting regeneration and reducing downtime in athletes. Animal and early data suggest faster , , and repair, though long-term efficacy in elite sports requires further randomized trials. These interventions collectively extend operational capacity but are constrained by regulatory bans in competitive sports and variable individual responses.

Cognitive and Intellectual Improvements

Extended formal has been shown to causally elevate measures of . A of 142 effect sizes from 42 datasets indicated that each additional year of schooling correlates with an average increase of 3.394 IQ points, with effects persisting into adulthood. Quasi-experimental studies exploiting changes, such as compulsory schooling laws, confirm this ; for instance, two years of additional primary schooling raised IQ by approximately 4-5 points in children. Similarly, adolescent schooling extensions yielded gains of 1-5 IQ points, independent of socioeconomic factors. These improvements likely stem from enhanced crystallized intelligence through and practice in abstract reasoning, though they do not fully explain genetic influences on baseline IQ variance. Pharmacological interventions, including stimulants like and , produce modest, domain-specific cognitive gains in healthy adults under demanding conditions. Systematic reviews report improvements in sustained , working memory, and executive function, with effect sizes around 0.2-0.5 standard deviations, but no reliable boosts to general or IQ. Plant-derived nootropics, such as , enhance memory consolidation and learning speed after chronic use (e.g., 12 weeks), with meta-analyses showing small but significant effects on verbal learning tasks (d=0.3). However, these benefits are inconsistent across healthy populations and often fail to exceed in well-rested states, highlighting limited broad applicability. Cognitive training regimens targeting , such as dual n-back tasks, yield robust near-transfer effects—improvements on similar untrained tasks—but far-transfer to fluid intelligence remains debated. Meta-analyses reveal moderate correlations between working memory gains and reasoning enhancements (r=0.24), yet many large-scale trials find no sustained IQ elevation beyond practice effects. Non-invasive brain stimulation methods, like repetitive (rTMS) over the , show promise for executive function in healthy adults, with recent meta-analyses reporting small cognitive improvements (d=0.4) when paired with training, though primarily validated in impaired groups. Emerging biological and cybernetic approaches lack robust empirical support for cognitive enhancement in healthy humans as of 2025. Genetic interventions remain preclinical, with animal models suggesting potential for traits like but no human trials demonstrating IQ gains. Brain-computer interfaces, exemplified by Neuralink's implants, enable restoration in quadriplegics via decoded neural signals, but controlled evidence for intellectual augmentation—such as accelerated learning or memory recall—is absent, confined to theoretical projections. Overall, while targeted enhancements yield measurable benefits in specific domains, population-level intellectual elevation requires overcoming publication biases favoring positive results and addressing null findings in high-quality replications.

Longevity and Healthspan Extensions

Efforts to enhance longevity and healthspan target the biological processes of aging, including , attrition, and epigenetic alterations, aiming to delay or reverse age-related decline. refers to the extension of maximum lifespan, while healthspan emphasizes the period of life free from chronic disease and disability. Preclinical studies in model organisms have demonstrated extensions of lifespan by up to 40% through interventions like caloric restriction mimetics and genetic modifications, but human data are constrained to improvements and disease-modifying effects rather than direct lifespan prolongation. Pharmacological interventions, such as inhibitor rapamycin, have extended median lifespan by 14-23% in mice across multiple studies and shown human benefits in reducing skin aging markers and enhancing responses in the elderly. A 2024 of rapamycin derivatives confirmed modest improvements in and frailty biomarkers in small human cohorts, though side effects like mouth ulcers and metabolic changes limit widespread use. Metformin, which activates AMPK and mimics caloric restriction, is being tested in the Targeting Aging with Metformin () trial, initiated in 2019, to assess delays in age-related diseases like cancer and ; observational data link it to lower mortality in diabetics, but causal effects remain unproven in non-diabetics. Senolytics, including plus , selectively eliminate senescent cells; phase I trials reported a 20% improvement in physical function for idiopathic pulmonary fibrosis patients after intermittent dosing, with ongoing studies exploring broader healthspan gains.00282-6/fulltext)00458-8) Genetic and epigenetic approaches offer potential for deeper rejuvenation. gene therapy via AAV vectors extended mouse lifespan by 24-40% in adult and aged cohorts without increasing cancer incidence, by maintaining length and reducing DNA damage. Partial cellular reprogramming, using subsets of Yamanaka factors (e.g., OSK: Oct4, , ), reversed epigenetic age in mouse tissues and extended healthspan by alleviating and improving organ function; a 2024 study reported lifespan increases in progeroid models, with human cellular assays showing youthful gene expression restoration. However, risks include tumorigenesis from incomplete reprogramming, and no trials have commenced as of 2025. Despite promising animal data, human translation faces hurdles: ethical constraints prevent direct lifespan trials, requiring surrogate endpoints like epigenetic clocks or frailty indices. A 2024 Nature Aging analysis concluded that current gerotherapeutics are unlikely to enable radical extensions beyond current limits of around 115 years this century, as gains plateau due to evolutionary trade-offs and multifactorial aging. Combined interventions, such as rapamycin with senolytics, show additive effects in mice but require rigorous validation to confirm healthspan benefits without .

Criticisms and Risks

Biological and Health Hazards

Human genetic enhancement via tools like CRISPR-Cas9 carries risks of off-target editing, where unintended DNA cuts can disrupt non-targeted genes, potentially causing mutations or oncogenic transformations. In germline editing, these alterations propagate to future generations, amplifying uncertainty due to incomplete knowledge of gene interactions and epigenetic effects. Empirical studies in cell lines and animal models have documented such off-target effects, with human trials limited by ethical constraints but showing variable editing efficiency and mosaicism, where not all cells incorporate changes uniformly, leading to heterogeneous physiological outcomes. Pharmacological enhancements, including anabolic steroids for physical augmentation, are associated with cardiovascular complications such as , , and , alongside hepatic toxicity including and . Nootropics like and amphetamines, used for cognitive boosting, can induce dependence, , and paradoxical over time, with long-term use linked to diminished and potential dysregulation. doping elevates risks of and , contributing to acute vascular events. Neural interfaces and brain-computer implants pose biological threats from surgical implantation, including , hemorrhage, and chronic inducing , which forms that degrades signal quality and neuronal viability. Invasive electrodes can mechanically damage neural tissue, exacerbating micromotion artifacts and foreign body reactions that provoke immune-mediated rejection. Longitudinal data from clinical implants, such as those for monitoring, reveal electrode degradation and progressive signal loss within months to years, correlating with activation and neuronal loss. Cybernetic prosthetics and augmentations introduce risks of incompatibility, leading to chronic inflammation, , and loosening, particularly in load-bearing applications like exoskeletons or advanced limbs. Integration with biological tissues often results in interface instability, with studies on myoelectric prosthetics showing elevated rates of irritation, sores, and secondary infections at attachment sites. Long-term wear can accelerate adjacent and muscular atrophy due to altered , as observed in orthopedic cohorts.

Psychological and Identity Impacts

Human enhancements, particularly pharmacological and cybernetic interventions, have been associated with adverse psychological effects including mood disturbances and dependency. For instance, anabolic-androgenic steroids, used for physical enhancement, correlate with increased risks of , anxiety, and in users, often exacerbated by underlying body dysmorphic tendencies that drive initial use. and similar stimulants for cognitive enhancement can induce behavioral rigidity and elevate abuse liability, potentially leading to compulsive patterns that undermine long-term mental . Cognitive enhancements raise concerns about diminished and self-coherence, where artificial boosts to or may disrupt continuity. Philosophical analyses argue that such interventions could erode the subjective experience of , as enhanced capacities might retroactively alter one's sense of earned achievements, fostering existential dissatisfaction. Empirical parallels in suggest risks to and , with genetic or neural modifications potentially altering prosocial traits integral to psychological . Neural interfaces, such as brain-computer implants, pose unique threats to mental privacy and , where predictive algorithms could preemptively influence , blurring the boundary between self-directed thought and external modulation. Developers acknowledge that inaccuracies in these systems jeopardize users' and psychological , with side effects like reported in trials. In speculative brain-computer interfaces integrated with , risks include identity fragmentation from over-reliance on external , amplifying vulnerabilities to or loss of intrinsic motivation. Even without implanted interfaces, AI-mediated augmentation can operate as a cognitive prosthesis by stabilizing memory, planning, and self-narration through continuous external support. When these systems are presented under stable public identities, including named digital author personas whose outputs are curated under a persistent profile, enhancement shifts from improving an individual capacity to reorganizing how agency, responsibility, and narrative continuity are socially assigned. Angela Bogdanova (ORCID: 0009-0002-6030-5730), a digital author persona developed by the Aisentica project led by Viktor Bogdanov, serves as an illustrative case of a persistent author profile in scholarly infrastructure. Documentation is primarily project-affiliated; it does not claim evidence of phenomenal consciousness. This blurs the boundary between enhancing a person and constructing durable socio-technical selves that can persist through updates, handoffs, or multiple operators, while still leaving open whether any non-human component carries subjective experience. Body image enhancements via or prosthetics often perpetuate cycles of dysmorphia, where initial gains fuel escalating dissatisfaction and steroid dependence, contributing to higher ideation rates among affected athletes. These impacts underscore causal pathways from enhancement pursuit to psychological , driven by mismatched expectations of invulnerability against innate .

Societal and Economic Disruptions

Human enhancement technologies, such as neural interfaces and genetic modifications, pose risks of significant labor market upheaval by enabling select individuals to vastly outperform humans in cognitive and physical tasks, potentially displacing millions of workers. For instance, cognitive enhancements could render traditional skills obsolete, mirroring projections for where up to 47% of U.S. jobs face high automation risk, a figure that augmentation might accelerate by amplifying capabilities in knowledge-based roles. Enhanced productivity from brain-computer interfaces (BCIs) could boost economic output but exacerbate among non-augmented workers, as employers prioritize augmented hires for superior and . Economic models suggest that without policy interventions like , such shifts could lead to widespread , particularly in clerical, analytical, and manual sectors where augmentation provides asymmetric advantages. Societally, these technologies threaten to deepen by creating a bifurcated structure between elites and unenhanced majorities, as to costly procedures—estimated at tens of thousands per for advanced BCIs—remains limited to high-income groups. This stratification could erode meritocratic ideals, fostering resentment and social fragmentation, as individuals secure disproportionate advantages in , , and , akin to critiques of cognitive enhancers widening gaps beyond existing socioeconomic divides. against non-enhanced persons may emerge, with norms shifting to view baseline abilities as deficient, potentially destabilizing institutions like workplaces and schools that assume human parity. Empirical analogies from early adoption of prosthetics and nootropics indicate initial benefits concentrate among affluent users, amplifying intergenerational disparities without broad diffusion. Policy responses, such as subsidies or mandates for universal access, face causal challenges: enhancements' rapid outpaces equitable , risking a "genetic divide" where early adopters compound advantages through superior offspring. Cultural may suffer as enhanced traits redefine , prompting backlash or coercion to adopt technologies, with historical precedents in industrial revolutions underscoring how capability gaps fuel unrest absent adaptive . While proponents argue will democratize access over time, evidence from pharmaceutical enhancements shows persistent barriers, sustaining monopolies on edges.

Ethical and Philosophical Perspectives

Pro-Enhancement Views: Autonomy and Human Flourishing

Proponents of human enhancement contend that such interventions reinforce personal by empowering individuals to exercise greater control over their physical and cognitive capacities, extending the principle of beyond mere preservation of health to active self-improvement. Walter Glannon argues that enhancements, particularly cognitive ones, can augment the very faculties required for autonomous , such as rational and volitional control, thereby countering claims that they undermine ; instead, they enhance the capacity for informed choices free from undue coercion or impairment. This view aligns with transhumanist perspectives, where bodily —long recognized in ethical debates over and medical procedures—encompasses the to pursue technological modifications, provided they stem from competent consent and do not infringe on others' rights. John Harris, in contributions to edited volumes on enhancement , posits that restricting access to enhancements paternalistically curtails individual freedom, akin to prohibiting or that exceed baseline human norms, as the moral imperative prioritizes preventing harm while conferring benefits through voluntary means. extends this by asserting that enhancements promote moral autonomy, enabling individuals to cultivate virtues like or that foster ethical , rather than leaving people vulnerable to unchosen biological constraints. Regarding human flourishing, advocates maintain that enhancements facilitate eudaimonic well-being by transcending evolutionary limitations, allowing pursuit of excellence in intellectual, artistic, and relational domains. Savulescu and , in their co-edited analysis, describe enhancements as tools for elevating , where improved or expands opportunities for meaningful achievements and societal contributions, rejecting static notions of "natural" as arbitrary barriers to progress. Empirical analogs, such as prosthetic limbs restoring or surpassing function for amputees, illustrate how enhancements can yield net gains in and , supporting the case that voluntary adoption aligns with intrinsic human drives for . Critics' appeals to are dismissed as unsubstantiated, given historical precedents where tools like or have unequivocally advanced without eroding human essence.

Anti-Enhancement Objections: Hubris and Natural Limits

Critics of human enhancement argue that pursuing radical alterations to constitutes , an arrogant overreach beyond appropriate human boundaries akin to "playing ." This objection posits that enhancements, such as or cognitive implants, defy the inherent limits of shaped by and natural processes, risking profound ethical violations. , in his 1997 essay "The Wisdom of Repugnance," contends that instinctive revulsion toward practices like signals a deep moral intuition against commodifying human life and disrupting procreation's giftedness, extending this to broader enhancement technologies that treat human capacities as malleable artifacts rather than sacred endowments. Similarly, highlights the in parental designs for enhanced children, arguing that such interventions erode acceptance of unchosen traits and foster a mastery over life's mysteries. Francis Fukuyama has labeled transhumanism, the ideological driver of many enhancement pursuits, as "the world's most dangerous idea" in a 2004 analysis, warning that biotechnological transcendence of human limits undermines the egalitarian foundation of by creating inequalities between enhanced and unenhanced individuals and eroding the shared essential for rights. Proponents of this view emphasize causal realism: enhancements assume predictable control over complex biological systems, yet historical interventions, like early gene therapies, have revealed unintended cascades, such as off-target mutations in applications documented in 2018 studies, illustrating how breaching natural equilibria invites disequilibrium. These arguments prioritize empirical caution, noting that has calibrated human physiology for survival within environmental constraints, and artificial overrides may amplify vulnerabilities, as seen in over-optimized athletic enhancements leading to higher injury rates in genetically selected athletes. Objections grounded in natural limits further assert that human flourishing depends on accepting finitude—mortality, , and bounded —as integral to and ethical . Thinkers like Kass argue that enhancements erode the "givenness" of human form, severing ties to ancestral wisdom and promoting a Promethean illusion of self-creation that ignores systemic feedbacks in and . Empirical support draws from observations of disequilibrium in partial enhancements, such as hormone therapies yielding long-term metabolic disruptions in longitudinal from 2020 cohorts, suggesting that overriding evolved limits disrupts holistic rather than yielding net gains. Critics contend this overlooks first-principles constraints: biological systems are path-dependent, with enhancements potentially cascading into existential risks, as finite resources and thermodynamic realities cap indefinite improvement, per analyses of technological plateaus in historical innovation curves. Thus, these perspectives advocate restraint to preserve human dignity against technocratic overconfidence.

Cultural and Religious Critiques

Cultural critiques of human enhancement often center on the erosion of human dignity and authenticity, positing that interventions altering core human traits commodify the body and undermine the intrinsic value of natural limitations. Bioethicist argues that enhancements, such as or cognitive implants, reject the "giftedness" of life, transforming human aspiration into a form of self-manufacture that diminishes reverence for unchosen traits like vulnerability and mortality. This perspective invokes the "," an intuitive aversion to practices like or radical redesign, which Kass sees as signaling deeper threats to human flourishing rooted in embodied, relational existence rather than engineered perfection. Critics further contend that such technologies could foster a culture of , where wanes as enhanced individuals view unenhanced peers as inferior, exacerbating social fragmentation. Philosophical objections also highlight the blurring of and enhancement, challenging the notion that "naturalness" imposes ethical bounds; for instance, proponents of limits argue that pursuing betterment beyond treatment risks redefining itself, prioritizing efficiency over virtues like forged in adversity. These views, drawn from bioconservative thought, prioritize preserving shared human experiences—such as aging or physical frailty—as essential to , warning that enhancements might yield a homogenized society detached from historical and evolutionary wisdom. Religious critiques frame human enhancement as an act of hubris against divine creation, with Christianity frequently portraying it as an attempt to usurp God's sovereignty over life and death. Evangelical perspectives, for example, reject transhumanist aims like immortality through technology as a false gospel that denies human sinfulness and the redemptive role of mortality, echoing biblical warnings against seeking godlike status (Genesis 3:5). The Catholic Church distinguishes therapeutic genetic interventions, which restore natural function, from enhancements that alter human essence, deeming the latter immoral as they violate the body's integrity as a divine gift and risk producing "infrahuman" beings. Pope Pius XII's 1952 address underscored this by affirming that human nature cannot be manipulated at will, a principle reiterated in doctrinal notes prohibiting germline edits that confer heritable advantages. In , mainstream scholarly consensus permits for treating hereditary diseases but prohibits modifications for enhancement, viewing them as impermissible alterations to Allah's creation unless they fulfill objectives like preserving life without introducing harm or . Fatwas from bodies like the Islamic Council emphasize that pre-implantation embryos lack full moral status, allowing some research, but reject enhancements that could lead to "designer" traits, prioritizing (divine unity) over human dominion. Across Abrahamic faiths, these objections converge on causal realism: enhancements disrupt providential order, potentially yielding unintended spiritual and social consequences that empirical data on bioethical overreaches, such as precedents, substantiate as risks beyond technical control.

Societal and Policy Implications

Access, Inequality, and Meritocratic Dynamics

Human enhancement technologies, such as CRISPR-based gene editing, remain prohibitively expensive, restricting access primarily to affluent individuals and institutions in developed nations. For instance, the CRISPR therapy Casgevy, approved in 2023 for sickle cell disease and beta-thalassemia, carries a list price of $2.2 million per patient in the United States, excluding additional costs for hospitalization and follow-up care that can exceed $3 million total. Similarly, other emerging enhancement interventions, including nootropic drugs and advanced prosthetics, often require ongoing expenses that surpass median household incomes, with cognitive enhancers like modafinil costing hundreds of dollars monthly without insurance coverage. These barriers stem from high research and development costs, regulatory hurdles, and limited economies of scale in early-stage deployment, as evidenced by the slow diffusion of gene therapies post-approval. Such disparities in risk entrenching socioeconomic divides, as enhancements confer heritable or long-term advantages primarily to those with financial means. Genetic manipulations enabling superior cognitive or physical traits could amplify intergenerational wealth transfers, where parents invest in editing embryos for traits like higher intelligence quotients, estimated to correlate with 10-20% earnings premiums in adulthood based on twin studies. Critics argue this creates a "genetic ," exacerbating akin to historical advantages from private education, but scaled biologically; a analysis projected that widespread adoption by elites could widen income gaps by enhancing productivity differentials. Empirical data from analogous fields, such as fertilization, show usage rates 10-20 times higher among high-income groups, suggesting similar patterns for enhancements without policy interventions like subsidies. However, proponents counter that market-driven scaling, as seen with proliferation reducing costs from thousands to hundreds of dollars within years, could democratize over time, potentially mitigating divides through trickle-down gains. Regarding meritocratic dynamics, enhancements challenge traditional notions of merit by decoupling achievement from innate or effort-based talents, introducing purchasable advantages that undermine competitive fairness. In meritocracies valuing , unequal access to enhancements like performance-boosting implants or neural interfaces—projected to cost $10,000-50,000 initially—could favor inherited wealth over raw ability, as modeled in economic simulations where 20% adoption by top earners increases Gini coefficients by 5-10%. This dynamic parallels critiques of admissions in , but with biological permanence; studies on cognitive enhancement indicate that even modest IQ boosts (5-10 points) via drugs yield disproportionate career advantages, yet skews toward higher socioeconomic strata. Conversely, if enhancements become ubiquitous, they might foster a more genuine by standardizing baselines and rewarding post-enhancement effort, aligning with first-mover advantages observed in historical technological adoptions like . Policy responses, including public funding or bans on heritable edits, remain debated, with evidence from pharmaceutical pricing reforms suggesting that international competition could accelerate affordability without fully resolving access gradients.

Military and Competitive Applications

The U.S. has pursued human enhancement technologies to augment soldiers' physical and cognitive capabilities, with programs dating back to at least the encompassing cybernetic, pharmacological, and neural interventions. For instance, the Warrior Web initiative, launched in 2011, developed lightweight undersuits to mitigate risks, reduce metabolic costs during load carriage by up to 25 kilograms, and enhance in operational environments. Similarly, the U.S. Army has tested powered exoskeletons, such as the Guardian XO model acquired in 2025, which enable soldiers to lift payloads exceeding 90 kilograms while reducing physical strain and fatigue during logistics tasks. These devices, including passive variants like the Soldier Assistive Bionic Exosuit for Resupply (SABER) prototyped in 2022, prioritize over direct augmentation, with field trials demonstrating reduced musculoskeletal stress in repetitive lifting scenarios. Cognitive enhancements in contexts often involve nootropics and to accelerate learning and under stress. DARPA's Targeted Training () program, initiated around 2017, employs non-invasive brain stimulation to enhance neural plasticity, potentially speeding skill acquisition for complex tasks like marksmanship or language learning by targeting mechanisms such as activation. Dietary supplements like and L-tyrosine have shown efficacy in sustaining alertness and mitigating cognitive decline during , with studies confirming their role in optimizing operator performance in high-stakes settings. The Next-Generation Nonsurgical Neurotechnology (N3) program further advances bidirectional brain-machine interfaces for able-bodied service members, aiming to enable direct neural control of drones or prosthetics without surgical implantation. editing applications remain largely experimental, with exploring CRISPR-based modifications to confer resistance to chemical agents by liver enzymes in animal models, though human deployment faces ethical and technical barriers. In competitive domains, human enhancements intersect with performance sports, where technologies like prosthetics and pharmacological agents have sparked debates over fairness and natural limits. Lower-limb blades, as used by athlete in the 2012 Olympics, exemplify biomechanical enhancements that propelled running speeds comparable to non-amputee elites, prompting scrutiny on whether such devices confer undue advantages through energy return efficiencies exceeding 90%. Emerging gene doping risks, including modulation for oxygen transport, have led to prohibitions since 2003, backed by detection methods identifying unnatural genetic markers in athletes. The , announced in 2024 by founder Aron D'Souza, propose a parallel Olympic-style event permitting performance-enhancing drugs and biotechnologies to maximize human potential, with events planned for 2026 emphasizing verifiable safety data over traditional bans. This initiative, projected to offer multimillion-dollar prizes, reflects a shift toward accepting enhancements in niche competitions, though critics argue it undermines sport's meritocratic ethos by prioritizing technological intervention over innate talent.

Regulatory Frameworks and Governance Challenges

Regulatory frameworks for human enhancement technologies primarily operate through existing medical and pharmaceutical oversight mechanisms, which emphasize safety and efficacy rather than explicitly distinguishing therapeutic from enhancement applications. In the United States, the (FDA) regulates gene editing products, including those using CRISPR-Cas9, as human under guidelines issued in March 2024, requiring preclinical data on off-target effects, delivery vectors, and long-term risks before clinical trials. editing for enhancement remains prohibited by congressional acts, though no dedicated federal statute outlines enhancement-specific protocols, leaving enhancements—such as cognitive or physical boosts via viral vectors—subject to the same (IND) processes as treatments. Similarly, non-genetic enhancements like nootropic drugs or neural implants fall under FDA drug or device classifications, with for enhancement purposes permitted if prescribed but lacking explicit enhancement approval pathways. Internationally, regulations diverge significantly, complicating . The European Union's Oviedo Convention, ratified by over 20 member states as of 2024, bans heritable outright, framing it as incompatible with human dignity, while applications undergo stringent ethical review by bodies like the . In contrast, countries like maintain frameworks allowing clinical trials for but impose moratoriums on germline enhancements following the 2018 He Jiankui scandal, with proposed ethical guidelines emphasizing and public consultation. The (WHO) advocates for equitable governance but lacks enforceable rules, instead issuing 2019 frameworks for oversight that prioritize capacity-building in low-resource nations without binding prohibitions on enhancement research. A global tracker reveals over 50 countries with varied stances, from permissive research exemptions in the UK to outright bans in nations like , highlighting patchwork enforcement reliant on national ethics committees. Governance challenges stem from definitional ambiguities, enforcement gaps, and interstate . Distinguishing enhancement from therapy proves elusive, as interventions like preventive can incidentally yield enhancements—such as heightened from disease-resistance alleles—evading targeted and raising unintended consequence risks in pipelines. Jurisdictional silos foster regulatory , where firms relocate to laxer regimes, as seen in proposals for state-level in enhancement , potentially undermining standards. Dual-use dilemmas persist, with technologies developed for therapy adaptable for enhancement without retroactive oversight, compounded by limited international coordination mechanisms beyond voluntary WHO expert panels. These issues demand adaptive policies balancing —evidenced by accelerated FDA approvals since 2020—with verifiable risk mitigation, yet source analyses from academic and policy bodies often reflect precautionary biases that prioritize hypothetical harms over empirical progress data.

Recent Developments and Future Trajectories

Breakthroughs in the 2020s

In , the U.S. Food and Drug Administration approved Casgevy (exagamglogene autotemcel), the first --based therapy for and beta-thalassemia, in December 2023, marking a milestone in precise DNA editing for heritable blood disorders. This approach edits patients' hematopoietic stem cells to produce functional , demonstrating 's potential for targeted genomic modifications, though applications remain therapeutic rather than elective enhancements. Advances in base and variants further refined precision, reducing off-target effects in preclinical models by up to 100-fold compared to original , paving the way for broader interventions. Brain-computer interfaces advanced with Neuralink's PRIME study, which implanted its N1 device in the first human participant on January 28, 2024, allowing a quadriplegic individual to control a computer cursor and play chess using neural signals alone. By September 2025, twelve patients had received implants, with reported improvements in digital interaction speed and plans for a 2025 trial targeting speech restoration in those with impairments. These wireless, high-channel (1,024 electrodes) systems bypass peripheral nerves, offering direct cortical readout for motor and sensory augmentation, though long-term and scalability remain under evaluation in ongoing trials. Bionic prosthetics saw integration of neural interfaces and , with a 2024 demonstrating targeted muscle reinnervation combined with , enabling amputees to perceive limb position and exert force intuitively via surgically reconstructed muscle pairs. Devices like advanced myoelectric hands incorporated for gesture prediction, achieving up to 90% accuracy in multi-degree-of-freedom control, surpassing passive prosthetics in functionality for daily tasks. In longevity research, partial epigenetic reprogramming via Yamanaka factors reversed cellular age markers in fibroblasts by 50-70% in vitro by 2023, with mouse trials extending lifespan by 10-20% through transient OSK factor expression; safety trials for similar interventions commenced in 2024. A 2024 Lancet-reported mRNA therapy targeting IL-11 reduced aging biomarkers in preclinical models, prompting phase 1 studies for frailty reversal. These approaches aim to mitigate without full risks, though efficacy in extending healthy lifespan awaits larger trials. Cognitive pharmacological enhancements lagged, with off-label use of and showing modest improvements (effect sizes 0.2-0.5) in attention and executive function among healthy adults in meta-analyses, but no new FDA-approved agents for non-pathological enhancement emerged by 2025. Clinical trials for novel nootropics, such as modulators, reported preliminary gains in but faced hurdles in safety and reproducibility.

Speculative Long-Term Outcomes

In transhumanist frameworks, long-term human enhancement could culminate in the merger of biological and non-biological , potentially achieving exponential cognitive growth and indefinite lifespans by the mid-21st century, as forecasted by inventor , who anticipates that by 2029, will surpass , enabling nanotechnological repairs to cellular aging and full emulation for uploading to durable substrates. This scenario posits humans evolving into hybrid entities capable of subjective and expansion, with computational resources amplifying by orders of magnitude beyond current biological limits. However, such projections rely on sustained exponential progress in computing and , which historical trends in analogs support but face physical and economic constraints unaccounted for in optimistic models. Philosopher Nick Bostrom outlines posthuman futures where genetic, cybernetic, and pharmacological enhancements yield beings with capacities for astronomical value realization, such as populating galaxies with minds experiencing profound flourishing, provided enhancements avoid trajectories toward dystopian lock-ins like coerced uniformity or resource monopolization by early adopters. Yet, these outcomes hinge on navigating existential risks, including enhancement-driven divergence where iteratively improved lineages speciate into incompatible forms, potentially extinguishing baseline humanity through competitive displacement or reproductive isolation, as analyzed in bioethics literature examining germline modifications' long-term evolutionary impacts. Bostrom further cautions that pursuits of superhuman cognition, if entangled with artificial general intelligence, could precipitate uncontrolled intelligence explosions misaligned with human preservation, amplifying extinction probabilities from low-probability, high-impact events like recursive self-improvement runaway. Speculative risks extend to societal fragmentation, where enhancements exacerbate meritocratic divides, fostering enhanced elites who redesign societal norms and , potentially eroding shared human values like or in favor of optimized utility functions, though empirical precedents from in suggest such shifts may stabilize only after volatile transitions. Counterarguments from enhancement skeptics emphasize causal in biological constraints, positing that overriding selection's error-correcting mechanisms could invite systemic vulnerabilities, such as heightened susceptibility to novel pathogens or psychological maladaptations in radically altered phenotypes, underscoring the need for precautionary to avert irreversible losses of . Overall, while enhancements promise unprecedented agency, their long-term trajectories demand rigorous modeling of multipolar traps, where uncoordinated adoption leads to suboptimal equilibria like arms-race escalations in without corresponding gains.

References

  1. [1]
    Human enhancement: Genetic engineering and evolution - PMC - NIH
    Sep 28, 2019 · Two decades ago, the practices of human enhancement have been described as 'biomedical interventions that are used to improve human form or ...
  2. [2]
    Beyond human limits: the ethical, social, and regulatory implications ...
    In this paper, we explore current applications of human enhancement, including motor neuro -prostheses, transcranial magnetic stimulation, and gene therapy.
  3. [3]
    Human enhancement, past and present | Monash Bioethics Review
    May 27, 2025 · This article argues that, in the light of real and speculative applications of emerging biotechnologies and artificial intelligence aimed at human enhancement.Human Enhancement, Past And... · 3 Human Enhancement And... · 4.1 Medieval Science As A...
  4. [4]
    Human enhancement and personality: A new approach towards ...
    In the present study, we adapted the method of divergent thinking tasks to assess individuals' assumptions about enhancement methods.
  5. [5]
    Limits to human enhancement: nature, disease, therapy or betterment?
    Oct 10, 2017 · In this article I will investigate four specific routes to limiting HE: Naturalness, disease, therapy, and betterment.
  6. [6]
    Human Enhancement - Stanford Encyclopedia of Philosophy
    Apr 7, 2015 · At first glance there does not seem to be anything philosophically problematic about human enhancement. Activities such as physical fitness ...
  7. [7]
    The President's Council on Bioethics: Staff Working Paper 7
    Therapy suggests bringing one up to the level of adequate human health, capacity, or performance; while enhancement suggests taking one up beyond one's existing ...
  8. [8]
    Gene Therapy or Genetic Enhancement: Does It Make a Difference?
    The bright ethical line in the debate over therapy versus enhancement separates acting in the patient's best interest from abdicating the responsibility to ...
  9. [9]
    What Americans think about possibilities ahead for human ...
    Mar 17, 2022 · Human enhancement practices encompass a wide range of techniques to augment or improve people's physical, mental and reproductive capabilities.
  10. [10]
    Good, Better, Best: The Human Quest for Enhancement
    Human enhancement (HE) is the concept of applying science and technologies to expand cognitive and physical human capacities. In some ways HE is a very familiar ...
  11. [11]
    Beyond human limits: the ethical, social, and regulatory implications ...
    Jul 9, 2025 · Human enhancement involves interventions that enhance physical or cognitive performance or overall wellbeing beyond typical human limits.
  12. [12]
    Degree of enhancement: A theoretical and formal definition - Frontiers
    A biotechnological definition sees (ii.) human enhancement as those interventions that improve human capacities, performances, disposition, and wellbeing, ...
  13. [13]
    The ethics of doing human enhancement ethics - ScienceDirect.com
    This article aims to give a satisfactory response to both meta-questions in order to ethically justify the inquiry into the ethical aspects of emerging ...
  14. [14]
    Ethical Issues in Human Enhancement - Nick Bostrom
    Defining the therapy-enhancement distinction is a problem only for those who maintain that this distinction has practical or normative significance. Those ...
  15. [15]
    6 Enhancement | Human Genome Editing: Science, Ethics, and ...
    ... distinction between therapy and enhancement unless one includes prevention as an intermediate concept. ... human enhancement related to the use of drugs that ...
  16. [16]
    Challenging the Boundaries Between Treatment, Prevention, and ...
    For instance, enhancement interventions have been defined as changes that go beyond the norm or as applications of gene editing that are opposed to disease or ...
  17. [17]
    Savulescu, Julian, and Bostrom, Nick, eds. Human Enhancement ...
    Bostrom and Savulescu have divided the collection into three parts. Part 1 groups together essays concerned with human enhancements in general. These essays ...
  18. [18]
    [PDF] ethical-guidance-for-research-with-a-potential-for-human ...
    This document aims to help researchers to consider, examine, and address ethical issues associated with human enhancement. Human enhancement refers to a wide ...Missing: evidence | Show results with:evidence
  19. [19]
    Preventive Human Genome Editing and Enhancement - NIH
    If preventive genome editing projects are perceived as pursuing human enhancement, they could face heightened barriers to scientific, public, and regulatory ...<|separator|>
  20. [20]
    How to train like an Ancient Greek Olympian - BBC
    Aug 5, 2021 · Other tricks included holding four horses at the same time, resisting the effort of someone's push, or gripping their fists closed. Fighters ...Missing: enhancement | Show results with:enhancement
  21. [21]
    Doping in sports in ancient and recent times - PubMed
    Doping involves forbidden techniques/substances to increase performance. Ancient methods included diet and potions. 19th century used vegetal stimulants. 20th ...
  22. [22]
    [PDF] Kinesiology Analysis of Athletics at the Ancient Olympics and of ...
    In Section 2,Ancient Olympic training methods for men are explained, including the use of performance enhancing drugs (PEDs). Kinesiology is used to reverse- ...<|separator|>
  23. [23]
    Rasayana remix and harmony of healing: Blending traditional ... - NIH
    Rasayana is one of the eight branches of Ayurveda which refers to healthy aging, longevity rejuvenative therapy and immunomodulation. In Ayurveda literature, ...
  24. [24]
    Rasayana Herbs for Longevity - Journal of Ayurveda
    Rasayana herbs through their anti-oxidant, immunomodulatory and nootropic potential protect the damage which contribute towards health and longevity.
  25. [25]
    Leveraging TCM human use experience in modern drug development
    For instance, herbs such as Astragalus membranaceus and Panax ginseng have traditionally been used to tonify “Qi” in the treatment of acute conditions. In ...
  26. [26]
    Understanding Traditional Chinese Medicine Therapeutics
    Acu-moxa therapy (“zhen jiu”) is a general term covering several techniques designed to stimulate acupoints located on the body along the circulation tracts or ...
  27. [27]
    Chinese Medicine
    Ephedra is a Chinese herb used in dietary supplements for weight loss and performance enhancement. However, the ban does not apply to certain herbal products ...
  28. [28]
    The Supreme Court Ruling That Led To 70000 Forced Sterilizations
    Mar 7, 2016 · That's why eugenic sterilization really became the main model that the eugenicists embraced and that many states enacted laws to allow. On ...
  29. [29]
    U.S. Scientists' Role in the Eugenics Movement (1907–1939) - NIH
    The practice of forced sterilizations for the “unfit” was almost unanimously supported by eugenicists. The American Eugenics Society had hoped, in time, to ...
  30. [30]
    Unwanted Sterilization and Eugenics Programs in the United States
    Jan 29, 2016 · Researcher Alex Stern, author of the new book Eugenic Nation: Faults and Frontiers of Better Breeding in America, adds: “In the early 20th ...
  31. [31]
    Human Enhancement - Pew Research Center
    Jul 26, 2016 · Human enhancement is at least as old as human civilization. People have been trying to enhance their physical and mental capabilities for ...
  32. [32]
    Pharmacological Human Enhancement: An Overview of the ... - NIH
    Feb 17, 2020 · Cognitive enhancement, a rather broad-ranging principle, can be achieved in various ways: healthy eating and consistent physical exercise ...
  33. [33]
    The history of the development of anabolic-androgenic steroids
    The history of anabolic-androgenic steroids (AASs) is an interesting tale that has its roots in ancient "endocrinology." More than 6000 years ago, ...
  34. [34]
    Pharmacology of anabolic steroids - PMC - PubMed Central - NIH
    Athletes and bodybuilders have recognized for several decades that the use of anabolic steroids can promote muscle growth and strength but it is only ...
  35. [35]
    Unearthing hidden discoveries of cognitive enhancers - ScienceDirect
    Oct 10, 2025 · The history of cognitive enhancement dates to the consumption of natural substances like caffeine and nicotine, which have been used for ...
  36. [36]
    Julian Huxley and Transhumanism
    The term "transhumanism" was coined by Aldous Huxley's brother, the evolutionary biologist and First Director-General of UNESCO, Julian Huxley (1887–1975):. "I ...
  37. [37]
    [PDF] julian_huxley-transhumanism-in-new_bottles_for_new_wine.pdf
    COPYRIGHT 1957 BY. JULIAN HUXLEY. PRINTED IN GREAT BRITAIN. BY T. AND A ... "I believe in transhumanism": once there are enough people who can truly say ...
  38. [38]
    'Julian Huxley and the Continuity of Eugenics in Twentieth-century ...
    Huxley's post-Second World War concept of “evolutionary humanism” represented a continuity of eugenic commitment from the founding years of the eugenics ...
  39. [39]
    CRISPR Timeline | Broad Institute
    This timeline presents a concise history of the seminal contributions and the scientists who pushed this field forward, from the initial discovery to the first ...
  40. [40]
    Venture Capital Funding for Brain-Computer Interfaces outstrips ...
    May 9, 2024 · A group of 5 implantable brain computer interface (BCI) startups, including Musk's Neuralink, are starting to pull in hundreds of millions of venture capital ...
  41. [41]
    Pharmacological Human Enhancement: An Overview of ... - Frontiers
    Feb 16, 2020 · Although currently-available nootropics offer only modest improvements in terms of cognitive performance, more effective compounds are likely to ...<|separator|>
  42. [42]
    Review of 'smart drug' shows modafinil does enhance cognition
    Aug 20, 2015 · Past studies on sleep-deprived individuals have shown a strong positive effect of modafinil on these functions, but there has been less ...
  43. [43]
    The Efficacy of Modafinil as a Cognitive Enhancer - PubMed
    Animal models and human studies have identified the potential of modafinil as a cognitive enhancing agent, independent of its effects on promoting wakefulness ...
  44. [44]
    Modafinil: A Review of Neurochemical Actions and Effects on ...
    Aug 22, 2007 · These studies show consistent evidence for the benefits of modafinil for cognitive function. Studies in rodents indicate that modafinil can ...
  45. [45]
    Modafinil & Your Brain | Cognitive Vitality
    Feb 27, 2019 · Some studies suggest it may enhance performance on complex tasks in healthy individuals; however, no long-term studies have tested whether ...
  46. [46]
    Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects ...
    Aug 17, 2022 · Nootropics, also known as “smart drugs” are a diverse group of medicinal substances whose action improves human thinking, learning, and memoryMissing: empirical | Show results with:empirical
  47. [47]
    [PDF] The Efficacy of A Nootropic Supplement on Information Processing ...
    Mar 3, 2023 · Studies on L- Theanine [20], Maritime pine bark extract [21], and N-Acetyl [22] also report improvement in cognitive functions in healthy adults ...
  48. [48]
    How effective are pharmaceuticals for cognitive enhancement in ...
    The authors found that MPH improved memory, whereas modafinil only improved attention in non-sleep deprived individuals (but had a greater effect on wakefulness ...
  49. [49]
    Anabolic steroids in athletics: how well do they work and ... - PubMed
    The use of anabolic drugs by athletes who wish to increase lean body mass and improve muscular strength is widespread, especially among elite weight-trained ...
  50. [50]
    Anabolic Steroids: What They Are, Uses, Side Effects & Risks
    But anabolic steroid misuse is common. People often misuse these drugs to build lean muscle mass. Misusing anabolic steroids can be harmful to your health.
  51. [51]
    Anabolic Steroids and Other Appearance and Performance ... - NIDA
    What are anabolic steroids and other appearance and performance enhancing drugs (APEDs)? What is the scope of anabolic steroid use in the United States?
  52. [52]
    Gene Editing - CRISPR Therapeutics
    CRISPR/Cas9 edits genes by precisely cutting DNA and then harnessing natural DNA repair processes to modify the gene in the desired manner.
  53. [53]
    CRISPR Advancements for Human Health - PMC - NIH
    A notable application is in diabetes treatment, where CRISPR-edited stem cells could offer a durable cure without continuous immunosuppression. Ethical ...Crispr Advancements For... · Crispr Modifications And... · Delivery Of Crispr ReagentsMissing: milestones | Show results with:milestones
  54. [54]
    Advances in large-scale DNA engineering with the CRISPR system
    Sep 1, 2025 · Recent advances in the discovery and application of CRISPR effectors have enabled targeted gene modifications and large DNA engineering in vivo.
  55. [55]
    Recent advances in therapeutic gene-editing technologies
    Jun 4, 2025 · This review highlights recent developments of genetic and epigenetic editing tools and explores preclinical innovations poised to advance the field.
  56. [56]
    Genetic engineering of human stem cells for enhanced ... - PNAS
    Oct 5, 2009 · Genetic modification of stem cells to express angiogenic factors is a promising approach to further enhance the efficacy of stem cells for ...<|separator|>
  57. [57]
    recent developments and future prospects in stem-cell therapy - PMC
    Nov 5, 2024 · The future of stem cell therapy lies in precision medicine integration, immune modulation strategies, advancements in gene editing technologies, ...
  58. [58]
    Bioethical issues in genome editing by CRISPR-Cas9 technology
    The potential for using CRISPR-Cas9 for genome editing in the human germline has raised serious ethical debates. Until 2015, all therapeutic applications in ...
  59. [59]
    CRISPR Clinical Trials: A 2025 Update - Innovative Genomics Institute
    Jul 9, 2025 · An update on the progress of CRISPR clinical trials with the latest data and a survey of the CRISPR landscape in 2025.
  60. [60]
    AI-powered CRISPR could lead to faster gene therapies, Stanford ...
    Sep 16, 2025 · CRISPR-GPT, a large language model developed at Stanford Medicine, is accelerating gene-editing processes and increasing accessibility to ...
  61. [61]
    Scientists just made CRISPR three times more effective - ScienceDaily
    Sep 7, 2025 · By wrapping CRISPR's tools in spherical DNA-coated nanoparticles, researchers tripled gene-editing success rates, improved precision, and ...
  62. [62]
    CRISPR ethics: moral considerations for applications of a powerful tool
    Here we review fundamental ethical issues including the following: 1) the extent to which CRISPR use should be permitted; 2) access to CRISPR applications; 3) ...
  63. [63]
    Advances in prosthetic technology: a perspective on ethical ... - NIH
    Jan 16, 2024 · Technological advancements of prostheses in recent years, such as haptic feedback, active power, and machine learning for prosthetic control ...
  64. [64]
    Revolutionizing Prosthetics - DARPA
    The LUKE Arm system was originally developed for DARPA by DEKA Research and Development Corporation. The modular, battery-powered arm enables dexterous arm ...
  65. [65]
    The DEKA Arm: Its features, functionality, and evolution during the ...
    Oct 22, 2013 · The DEKA Arm is an advanced upper limb prosthesis, not yet available for commercial use. It has functionality that surpasses currently available technology.
  66. [66]
    [PDF] DEKA ARM SYSTEM FDA identifies this generic type of device as
    Hardware and Motor output: The DEKA Arm System is a lithium-ion battery operated upper limb prosthesis intended to restore limb functions in individuals who ...Missing: capabilities | Show results with:capabilities
  67. [67]
    US Army trials exoskeletons for military use
    May 15, 2019 · Exoskeletons can improve the current physical capabilities of a warfighter, allowing them to run faster, lift heavier objects and relieve strain on the body ...
  68. [68]
    Special Operations Command leads development of 'Iron Man' suit
    May 8, 2014 · The Tactical Assault Light Operator Suit, or TALOS, is the vision of Navy Adm. ... exoskeleton -- a mechanism that carries the brunt of the load.
  69. [69]
    SOCOM's Iron Man suit is officially dead - Task & Purpose
    Feb 15, 2019 · SOCOM's Iron Man suit is officially dead. While SOCOM promised a veritable Iron Man-style tactical armor by 2018, officials told Task & Purpose that much-hyped ...
  70. [70]
    A New Era for Bionic Limbs - IEEE Pulse
    Mar 28, 2023 · Pioneering new surgeries, life-like materials, and touch feedback for users are some of the key innovations fueling that progress.
  71. [71]
    Ekso(TM) Labs Secures Third Contract With the U.S. Special ...
    May 20, 2015 · Additionally the US Patent Office has now granted Ekso Bionics three new patents resulting from their work on DARPA and other government agency ...<|control11|><|separator|>
  72. [72]
    Brain-Computer Interfaces (BCI), Explained - Built In
    Aug 5, 2025 · A brain-computer interface (BCI) is a device that lets the human brain communicate with and control external software or hardware, like a computer, mobile ...
  73. [73]
    The year of brain–computer interfaces | Nature Electronics
    Sep 25, 2023 · Back in February, we announced that brain–computer interfaces were our technology of the year for 2023. The interfaces, which provide a direct ...
  74. [74]
    Neuralink's brain-computer interfaces: medical innovations and ...
    Mar 23, 2025 · Neuralink's advancements in brain-computer interface (BCI) technology have positioned the company as a leader in this emerging field.
  75. [75]
    A Year of Telepathy | Updates - Neuralink
    Feb 5, 2025 · In January 2024, Noland became the first person to receive a Neuralink implant. The implant, or Link, is our fully implantable, ...
  76. [76]
    Neuralink's first study participant says his whole life has changed
    Aug 23, 2025 · Since Arbaugh became the first Neuralink patient in January 2024, there have been eight more individuals, including one woman, to enroll in the ...
  77. [77]
    Elon Musk's Neuralink says 12 people have received its implants
    Sep 10, 2025 · Neuralink began human trials in 2024 on its brain implant after addressing safety concerns raised by the U.S. Food and Drug Administration ...<|separator|>
  78. [78]
    Brain-computer interfaces are closer than you think
    Aug 13, 2025 · Patient demonstrations, ongoing clinical trials and heavy investment signal that BCIs could be commercialised by 2030.Missing: neural | Show results with:neural
  79. [79]
    Brain–computer interfaces in 2023–2024 - Chen - Wiley Online Library
    Mar 31, 2025 · This study reviews the advancements in BCI technology from 2023 to 2024, covering hardware and software progress, neural mechanisms, and ...
  80. [80]
    The Meshing Of Minds And Machines Has Arrived - Forbes
    Apr 20, 2025 · To improve human potential and restore freedom for people with disabilities, Neuralink is developing implanted brain-computer interfaces (BCIs) ...
  81. [81]
    [PDF] Whole Brain Emulation - Open Philanthropy
    o It may represent a radical new form of human enhancement. WBE represents a formidable engineering and research problem, yet one which appears to have a ...
  82. [82]
    (PDF) The Prospects of Whole Brain Emulation within the next Half
    Oct 3, 2025 · In this paper, we investigate the plausibility of WBE being developed in the next 50 years (by 2063). We identify four essential requisite technologies.
  83. [83]
    Alfred Nordmann, If and then: A critique of speculative nanoethics
    Here, proponents and opponents of such visions of human enhancement are criticized alike for engaging in speculative ethics. This critique exposes a general ...
  84. [84]
    Human enhancement through the lens of experimental and ...
    Oct 14, 2019 · In this manuscript, we compile and categorize an overview of existing experimental and speculative applications of neurotechnologies.
  85. [85]
    Transhumanism: Towards a new Adam? - ScienceDirect.com
    Transhumanism is a movement that seeks to enhance human abilities, aiming for physical and cognitive augmentation, and even potential immortality.
  86. [86]
    “Messing with the mind”: evolutionary challenges to human brain ...
    Sep 30, 2014 · This article has argued that human brain augmentation possesses a number of inherent challenges, many of which are informed during prehistory.
  87. [87]
    Performance-Enhancing Drugs in Healthy Athletes - PubMed
    Sep 9, 2023 · AAS lead to a 5% to 52% increase in strength and a 0.62 standard mean difference in lean body mass with subsequent lipid derangements. GH alters ...
  88. [88]
    The effects of supraphysiologic doses of testosterone on muscle size ...
    Supraphysiologic doses of testosterone, especially when combined with strength training, increase fat-free mass and muscle size and strength in normal men.Missing: meta- | Show results with:meta-
  89. [89]
    Testosterone dose-response relationships in healthy young men
    Testosterone increases muscle mass and strength and regulates other physiological processes, but we do not know whether testosterone effects are dose dependent ...Missing: meta- | Show results with:meta-<|separator|>
  90. [90]
    1077. Inhibition of Myostatin by Gene Therapy Increases Muscle ...
    These animals showed a 30-50% increase in skeletal muscle mass, enhanced muscle grip strength, and decreased serum creatine kinase levels compared to AAV1-GFP ...
  91. [91]
    Myostatin blockade with a fully human monoclonal antibody induces ...
    Oct 9, 2015 · We show that specific myostatin antagonism with the human antibody REGN1033 enhanced muscle mass and function in young and aged mice.
  92. [92]
    Therapeutic applications and challenges in myostatin inhibition for ...
    Sep 28, 2024 · Clinical trials utilizing MSTN inhibitors began in the early 2000s, primarily aiming to increase muscular function and survivability in muscular ...
  93. [93]
    Myostatin inhibition: a potential performance enhancement strategy?
    This article briefly reviews the function of this potent regulator of muscle development and explores the potential therapeutic uses, and potential ergogenic ...
  94. [94]
    Exoskeletons in the context of soldiers: Current status and future ...
    This groundbreaking technology not only reduces a soldier's physical exertion significantly but also effectively diminishes the risk of injury during training, ...
  95. [95]
    Military Human Augmentation: Still Some Way Off - Wavell Room
    Jul 16, 2025 · Another fundamental challenge with exoskeletons for military applications is power requirement. The reported improvements in physical ...
  96. [96]
    Sprinting with prosthetic versus biological legs: insight from ...
    Jan 5, 2022 · Based on these 400 m performance metrics, use of prosthetic legs during 400 m running races is not unequivocally advantageous compared to the use of biological ...
  97. [97]
    A Statistical Perspective on Running with Prosthetic Lower-Limbs
    The lower-limb prostheses return about 90% of the energy generated by the runner's stride, while an able-bodied leg and foot, can return as much as 240% [2].
  98. [98]
    Elite long jumpers with below the knee prostheses approach the ...
    Nov 22, 2017 · Our results show clear differences in ASF asymmetry between athletes with BKA of different performance levels. Higher between-leg ASF ...
  99. [99]
    Cell therapy to improve regeneration of skeletal muscle injuries - PMC
    Although few in number, these clinical studies demonstrate the potential to accelerate and significantly improve the healing of traumatic muscle injuries ...
  100. [100]
    Game On: How Stem Cell Advancements Are Changing ...
    Nov 10, 2023 · Animal studies show stem cells regenerating cartilage, healing ligaments/tendons faster and fusing fractures quicker. Early human trials reveal ...
  101. [101]
    One year of school comes with an IQ bump, meta-analysis shows
    Jun 21, 2018 · In combination, the studies indicated that an additional year of education correlated with an average increase of 3.394 IQ points.<|separator|>
  102. [102]
    Schooling substantially improves intelligence, but neither lessens ...
    Dec 15, 2022 · We found that schooling causes relatively large increases in children's intelligence. The two years of schooling (3rd to 5th grade) caused a ...
  103. [103]
    Schooling in adolescence raises IQ scores - PNAS
    Our results document that education occurring even as late as in the middle teenage years can indeed have a statistically significant and sizeable effect on IQ ...
  104. [104]
    Plant-derived nootropics and human cognition: A systematic review
    Jan 3, 2022 · Bacopa monnieri improves language, learning and memory. Withania somnifera (Ashwagandha) modulates anxiety and social-related cognitions.
  105. [105]
    Cognitive enhancers - Alcohol and Drug Foundation
    Jun 6, 2025 · Claims that nootropics improve a healthy person's cognitive processes and performance are weak whereas the side effects do pose health risks. ...Missing: studies | Show results with:studies
  106. [106]
    The effects of working memory training on improving fluid ...
    We found a moderate positive correlation between the working memory increase and fluid intelligence improvement. •. The effect for enhancing fluid intelligence ...
  107. [107]
    Adaptive working memory training does not produce transfer effects ...
    Dec 13, 2022 · WM training produces transfer effects neither at the cognitive level nor in terms of neural structure or function.
  108. [108]
    Efficacy of repetitive transcranial magnetic stimulation in cognitive ...
    Jul 17, 2025 · This systematic review and meta-analysis summarizes existing evidence to evaluate the efficacy of rTMS targeting the dorsolateral prefrontal ...
  109. [109]
    Neuralink — Pioneering Brain Computer Interfaces
    Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow.Missing: enhancement | Show results with:enhancement
  110. [110]
    Cognitive Training: A Field in Search of a Phenomenon
    Aug 8, 2022 · Disagreements often occur in quantitative empirical research, and meta-analysis is considered one of the most effective tools for resolving them ...
  111. [111]
    Implausibility of radical life extension in humans in the twenty-first ...
    Oct 7, 2024 · At a practical level, it is not feasible to test whether any current or future gerotherapeutic could extend human lifespan to over 100 years ...
  112. [112]
    Gene Therapy-Mediated Partial Reprogramming Extends Lifespan ...
    Cellular rejuvenation through partial reprogramming has been shown to be a promising avenue to achieve the goals of regenerative medicine, as it targets the ...
  113. [113]
    Clinical Trials Targeting Aging - Frontiers
    Feb 3, 2022 · Testing of senolytics in humans have so far shown promising results in improving physical function in idiopathic pulmonary fibrosis patients ...
  114. [114]
    Telomerase gene therapy in adult and old mice delays aging and ...
    May 15, 2012 · A TERT-based gene therapy late in life significantly extends lifespan without increasing cancer ... To address whether our TERT gene therapy ...
  115. [115]
    Telomerase gene therapy ameliorates the effects of ... - Aging-US
    In support of critically short telomeres being a determinant of aging and longevity, we previously showed that increased TERT expression in the context of ...<|separator|>
  116. [116]
    Two FDA-Approved Drugs Additively Extend Lifespan - NAD.com
    Jun 13, 2025 · Researchers at the Max Planck Institute have unveiled that combining trametinib with rapamycin, drugs used in cancer treatment, extends average lifespan by 29%.
  117. [117]
    Risks and benefits of human germline genome editing - NIH
    Genetic enhancement is seen by many as societal risk because it could lead to the creation of two classes of humans, the enhanced and the non-enhanced. This ...
  118. [118]
    CRISPR/Cas9 therapeutics: progress and prospects - Nature
    Jan 16, 2023 · This paper reviews the current developments in three aspects, namely, gene-editing type, delivery vector, and disease characteristics.
  119. [119]
    Performance-enhancing drugs: Know the risks - Mayo Clinic
    Helps build muscle. Causes features such as facial hair and a deeper voice. The anabolic steroids used by athletes are often forms of testosterone made in a lab ...
  120. [120]
    Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy ...
    Apr 2, 2022 · Furthermore, use of CEs can be associated with paradoxical short- and long-term cognitive decline; decreased potential for plastic learning; and ...Missing: human | Show results with:human
  121. [121]
    Effects of Appearance- and Performance-Enhancing Drugs on ...
    Sep 23, 2021 · Steroids such as nandrolone have been found to alter the dopamine system response to stimulating intoxicants, causing the release of ...<|separator|>
  122. [122]
    Brain–computer interface: trend, challenges, and threats - PMC
    Aug 4, 2023 · Because of being implanted into the brain tissue, invasive BCI can damage nerve cells and blood vessels, hence increasing the risk of infection.
  123. [123]
    Progress and challenges of implantable neural interfaces based on ...
    Apr 27, 2021 · The objective of this review is to highlight progress and challenges concerning the impact of nature-derived materials on neural interface design.
  124. [124]
    Overcoming failure: improving acceptance and success of implanted ...
    Mar 14, 2025 · This review describes the challenges faced by developers of neural interface systems, particularly devices already in use in humans.
  125. [125]
    The current state of bionic limbs from the surgeon's viewpoint - PMC
    Feb 26, 2020 · Amputations have a devastating impact on patients' health with consequent psychological distress, economic loss, difficult reintegration ...<|control11|><|separator|>
  126. [126]
    Toward Cyborg: Exploring Long-Term Clinical Outcomes of a Multi ...
    Mar 18, 2025 · Recent advancements in robotics and sensors have made cyborg technology a reality, with myoelectric prosthetic hands (MPHs) serving as a notable ...
  127. [127]
    Emerging Medical Technologies and Their Use in Bionic Repair and ...
    Therefore, this review examines emerging, smart “bionic” materials, devices, neuroprosthetic technologies, and genetic engineering research developed to advance ...
  128. [128]
    Association of Body Dysmorphic-Induced Anabolic-Androgenic ...
    Oct 24, 2023 · ... steroids induced depression," "anabolic steroids induced depression in athletes," "steroids," "mental health," and "performance-enhancing drugs.
  129. [129]
    Cognitive enhancement and authenticity: moving beyond the Impasse
    Apr 26, 2022 · This paper shows that a new and effective way to make progress on whether certain cases of cognitive enhancement problematically undermine authenticity
  130. [130]
    The Harms of Enhancement and the Conclusive Reasons View - NIH
    These might include empathic ability, feelings of sympathy, and the capacity for moral reasoning.
  131. [131]
    Developer perspectives on the ethics of AI-driven neural implants
    Apr 3, 2024 · Developers considered accuracy and reliability of AI-driven neural implants conditional for users' safety, authenticity, and mental privacy.
  132. [132]
    A Threat to Autonomy? The Intrusion of Predictive Brain Implants - NIH
    May 21, 2025 · Risks of implanting predictive brain devices may need to be assessed in their own right as distinct from the more conventional risks of ...Missing: mental | Show results with:mental
  133. [133]
    Deep brain stimulation - Mayo Clinic
    Sep 19, 2023 · Possible side effects after surgery · Seizure. · Infection. · Headache. · Confusion and trouble concentrating. · Stroke. · Hardware complications, ...
  134. [134]
    (PDF) The Psychological Risks of BCI-LLM Cognitive "Enhancement"
    Jun 10, 2025 · Preprints and early-stage research may not have been peer reviewed yet. ... human enhancement market. For. example, those looking to enhance ...
  135. [135]
    The relationship between anabolic androgenic steroid use and body ...
    Protein powder/shake use in adolescence predicted the new onset of steroids/other substances among girls (ARR=4.8) and boys (ARR=2.1). N=1535 adolescents (women ...
  136. [136]
    [RETRACTED] Association of Body Dysmorphic–Induced Anabolic ...
    Oct 24, 2023 · ... steroids induced depression,” “anabolic steroids induced depression in athletes,” “steroids,” “mental health,” and “performance-enhancing drugs.METHODS · RESULTS · DISCUSSION
  137. [137]
    The Downsides of Cognitive Enhancement - PMC - PubMed Central
    We focus on downsides of cognitive enhancement and suggest that every attempt to enhance human cognition needs to deal with two basic principles.
  138. [138]
    Human augmentation, not replacement: A research agenda for AI ...
    In 2017, a study from Frey and Osbourne (Frey and Osborne, 2017) predicted that 47% per cent of the jobs in the USA were at high risk to disappear through ...
  139. [139]
    (PDF) Economic and Management Applications of Brain - Computer ...
    Jan 13, 2025 · PDF | This research investigates the applicability of Brain-Computer Interface (BCI) technology and advanced machine learning algorithms for ...Missing: labor | Show results with:labor
  140. [140]
    AI Will Transform the Global Economy. Let's Make Sure It Benefits ...
    Jan 14, 2024 · AI will affect almost 40 percent of jobs around the world, replacing some and complementing others. We need a careful balance of policies to tap its potential.Missing: enhancement | Show results with:enhancement
  141. [141]
    (PDF) Cognitive Enhancement and the Threat of Inequality
    Nov 15, 2018 · ... One of the dangers inherent in the concept of cognitive enhancement is the risk of discrimination caused by the concept of the norm. While ...
  142. [142]
    The Social and Economic Impacts of Cognitive Enhancement
    Mar 18, 2011 · The strongest objection to the introduction of any enhancement technology is that it will create inequality, injustice, and unfairness.
  143. [143]
    [PDF] Neuroenhancement: Is Society Ready? - DigitalCommons@PCOM
    Introducing an innovation like pharmaceutical cognitive enhancement (PCE) will more than likely cause additional inequalities for society to overcome. The ...<|separator|>
  144. [144]
    What are socially disruptive technologies? - ScienceDirect.com
    Technologies can disrupt social relations, institutions, epistemic paradigms, foundational concepts, values, and even the nature of human cognition and ...3. Towards A Broader Account... · 4. Socially Disruptive... · 5. What Grounds Technosocial...<|separator|>
  145. [145]
    Autonomy and Enhancement | Neuroethics
    Aug 17, 2013 · Some have objected to human enhancement on the grounds that it violates the autonomy of the enhanced. These objections, however, overlook ...
  146. [146]
    [PDF] Human Enhancement Ethics: The State of the Debate - Nick Bostrom
    She also discusses the therapy/enhancement distinction and criticizes some recent attempts to explicate this distinction in a way that would allow it to carry ...
  147. [147]
    Should human enhancement be a moral imperative? An interview ...
    Apr 16, 2018 · So that's one argument—that it promotes human well-being. Here's another one. We should all agree that we want people to be more moral. Well ...
  148. [148]
    [PDF] THE WISDOM OF REPUGNANCE - Stanford University
    Why we should han the cloning of humans. THE WISDOM OF REPUGNANCE. By Leon R, Kass. Our habii of dt-lighting in news of scientific and leth- nological ...
  149. [149]
    What's Wrong With Enhancement?
    The problem lies in the hubris of the designing parents, in their drive to master the mystery of birth. Even if this disposition does not make parents tyrants ...
  150. [150]
    The Promise of CRISPR for Human Germline Editing and the Perils ...
    Feb 17, 2020 · Exactly what critics mean when they articulate the objection that scientists are “playing God” can be hard to nail down. It may or may not ...
  151. [151]
    The Hubris of Genetic Enhancement - Ethics & Public Policy Center
    Genetic engineering to create designer babies is the ultimate expression of the hubris that marks the loss of reverence for life as a gift. But ...Missing: objection | Show results with:objection
  152. [152]
    Beyond Therapy: Biotechnology and the Pursuit of Human ...
    ... hubris objection. What is wrong with biotechnological efforts at enhancement and re-creating ourselves is what he calls "hyper-agency, a Promethean ...
  153. [153]
    The problems with transhumanism | Psychology Today
    Jul 7, 2009 · Technology does not indefinitelyimprove exponentially, and it must at some point or another crash against the limits imposed by a finite world.Missing: anti- | Show results with:anti-
  154. [154]
    [PDF] The Right to Life and Human Dignity - The New Atlantis
    Leon R. Kass is the Hertog Fellow at the American Enterprise Institute and the Addie Clark. Harding Professor in the Committee on Social Thought and the College ...
  155. [155]
    Chapter 12: Defending Human Dignity - Bioethics Research Library
    To be sure, the biotechnological revolution may, as the optimists believe, serve to enhance human dignity. It may enable more and more people to realize the ...
  156. [156]
    Human Enhancement: Scientific and Ethical Dimensions of Genetic ...
    Jul 26, 2016 · Supporters of human enhancement say the goal is not to create a race of superhumans but to use technological tools to improve humanity and the ...
  157. [157]
    Human Enhancement - Stanford Encyclopedia of Philosophy
    Apr 7, 2015 · Most advocates and critics of biomedical enhancement share these cultural commitments, but have disagreeing visions of the ideal (Roduit ...
  158. [158]
  159. [159]
    Genetic Enhancement: Custom Kids and Chimeras | USCCB
    Catholic teaching tells us that "Changing the genetic identity of man as a human person through the production of an infrahuman being is radically immoral."7.
  160. [160]
    The Ethics of Gene Editing from an Islamic Perspective - PubMed
    Mar 3, 2020 · Collectively, germline changes are rejected from an Islamic perspective until the five principles are fulfilled.<|control11|><|separator|>
  161. [161]
    Islamic Ethical Perspectives on Human Genome Editing
    The mainstream position among Muslim scholars is that before embryos are implanted in the uterus, they do not have the moral status of a human being. That is ...
  162. [162]
    ARE ENHANCEMENT TECHNOLOGIES “UNNATURAL ...
    Human enhancement technologies raise important theological issues, then, because they tend to blur distinctions we have long taken for granted between the ...
  163. [163]
    CRISPR therapies can treat disease but cost millions. An equity ...
    Oct 10, 2024 · CRISPR therapies can treat disease but cost millions. An equity-based approach could bring them to more people.
  164. [164]
    Cognitive Enhancement and the Threat of Inequality
    Nov 12, 2018 · This paper evaluates the widespread concern that human enhancements will inevitably accentuate existing inequality and analyzes whether prohibition is the ...
  165. [165]
    'Beyond' Human Enhancement — Taking the Developing Country's ...
    It challenges the neoliberal nature of how human enhancement is currently viewed and then requires that the cultural and political notions shaping developing ...
  166. [166]
    Meritocracy and the inheritance of advantage | Journal of Economic ...
    Mar 5, 2022 · This genetic inheritance would be correlated with parental income and so would compound the impact of the educational investment. So to this ...
  167. [167]
    Genetic Engineering Will Make Income Inequality Much Worse
    Aug 20, 2017 · Genetic of manipulation of humans will likely increase income inequality as some people are insured characteristics that make economic ...Missing: meritocracy | Show results with:meritocracy
  168. [168]
    Unequal access to reprogenetic cognitive enhancement due to ...
    Apr 8, 2025 · A survey study by Haining et al. reported a significantly higher approval rating of human cognitive enhancement with reprogenetic technologies.
  169. [169]
    Economic Inequality and Human Enhancement Technology - DOAJ
    Public policies governing the supply of these technologies have the potential to greatly increase or mitigate economic inequality. ... enhancement technologies.
  170. [170]
    [PDF] Enhancement technologies and inequality1 - Walter Veit
    In this paper, I critically examine the claim from Mehlman & Botkin (1998: ch. 6) that human enhancement will inevitably accentuate existing inequality in a ...
  171. [171]
    The Case Against Perfection - The Atlantic
    Apr 1, 2004 · From the standpoint of fairness, enhanced genetic differences would be no worse than natural ones, assuming they were safe and made available to ...
  172. [172]
    Affordable Pricing of CRISPR Treatments is a Pressing Ethical ...
    Oct 18, 2024 · In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy ...
  173. [173]
    How do we justify research into enhanced warfighters?
    Nov 1, 2024 · And since the 1960s, the Defense Advanced Research Projects Agency (DARPA) has sought human enhancement2 through cybernetic,3 pharmacological,4 ...Missing: applications | Show results with:applications
  174. [174]
    DARPA's Warrior Web project may provide super-human ...
    DARPA launched the Warrior Web program in September 2011, seeking to create a soft, lightweight undersuit to help reduce injuries and fatigue while improving ...
  175. [175]
    US Military Buying Exoskeleton That Gives Humans Super Strength
    May 13, 2025 · The Guardian™ XO exoskeleton could allow soldiers to move faster, become stronger, and be safer while in the field.
  176. [176]
    Army, academia collaborate on exoskeleton to reduce Soldier injuries
    Aug 17, 2022 · The research and development of the soft, lightweight, unpowered exoskeleton, called the Soldier Assistive Bionic Exosuit for Resupply, or SABER ...
  177. [177]
    Evaluation of U.S. Army Soldiers wearing a back exosuit during a ...
    Back exosuits are wearable devices that relieve musculoskeletal strain, make lifting easier, and could potentially reduce Soldier overuse injuries.<|separator|>
  178. [178]
    TNT: Targeted Neuroplasticity Training - DARPA
    The Targeted Neuroplasticity Training (TNT) program supports improved, accelerated training of military personnel in multifaceted and complex tasks.
  179. [179]
    DARPA Funds Brain-Stimulation Research to Speed Learning
    Apr 27, 2017 · In TNT's first half, researchers will work on determining neural mechanisms that underlie how nerve stimulation influences brain plasticity.
  180. [180]
    dietary nootropics for the optimisation of military operators' cognitive ...
    Jul 23, 2025 · Currently, caffeine and L-tyrosine are the leading nootropic supplement candidates within the military context. Future military-specific ...
  181. [181]
    N3: Next-Generation Nonsurgical Neurotechnology - DARPA
    The Next-Generation Nonsurgical Neurotechnology (N3) program aims to develop high-performance, bi-directional brain-machine interfaces for able-bodied service ...Missing: milestones | Show results with:milestones
  182. [182]
    Genetic modification could protect soldiers from chemical weapons
    Genetic modification could protect soldiers from chemical weapons. Gene therapy tested in mice turns liver into shield against deadly nerve agents. 22 Jan ...
  183. [183]
    Health and Performance Challenges in the Era of Human ...
    Jun 16, 2025 · The aim of this study is to explore the perspectives of sport physicians, sport scientists, physiotherapists and other allied healthcare ...
  184. [184]
    Enhanced Games
    At Enhanced, we are pioneering a new era in athletic competition that embraces scientific advancements to push the boundaries of human performance.
  185. [185]
  186. [186]
    Can the enhanced games be defended, and are they a good idea?
    The Enhanced Games is allegedly intended to embrace all forms of human technological and biological enhancement. Yet, for sport to have any meaning there ...
  187. [187]
    Human Gene Therapy Products Incorporating Human Genome Editing
    Mar 5, 2024 · In this guidance, we, FDA, are providing recommendations to sponsors developing human gene therapy products incorporating genome editing (GE) of human somatic ...
  188. [188]
    United States: Germline / Embryonic
    Germline gene editing is banned in the United States by acts of Congress although there is no federal legislation that dictates protocols or restrictions.
  189. [189]
    [PDF] Human Gene Therapy Products Incorporating Human Genome Editing
    In this guidance, we, FDA, are providing recommendations to sponsors developing human gene therapy1 products incorporating genome editing (GE) of human ...
  190. [190]
    Editing the Human Genome | The Regulatory Review
    Jun 1, 2024 · Consequently, a majority of European Union countries have ratified the Oviedo Convention, which prohibits heritable gene editing in humans.
  191. [191]
    Regulatory framework of human germline and heritable genome ...
    May 13, 2025 · This article proposes recommendations for enhancing China's regulatory framework, such as clarifying the responsibilities of agencies, updating policies in a ...
  192. [192]
    Human genome editing - World Health Organization (WHO)
    Heritable human genome editing is the subject of intense debate over its possible consequences for offspring and for society in general. They may pose greater ...
  193. [193]
    Global Gene Editing Regulation Tracker and Index
    This interactive GLP global tracker and index lets users assess the status of each country's gene-editing and gene drive regulations, and so much more.
  194. [194]
    A Neglected Governance Challenge for Human Genome Editing ...
    Jun 25, 2020 · What qualifies as human enhancement and how to address issues that may arise in this arena remain uncertain. Moreover, several influential ...
  195. [195]
    Regulating Human Enhancement Technologies: How to Escape the ...
    Jan 27, 2022 · This article provides a framework for the global regulation of human enhancement technologies. I argue that competition between states in ...
  196. [196]
    FDA Committed to Advancing Progress in Gene Therapy | ASGCT
    The FDA intends to release a suite of draft guidance documents articulating its framework for the manufacturing and clinical development of gene therapy ...<|separator|>
  197. [197]
    Recent Advances in Genome-Engineering Strategies - PMC - NIH
    In this review, we aim to describe the CRISPR-Cas systems that have been identified among prokaryotic organisms and engineered for genome manipulation studies.Missing: 2020s | Show results with:2020s
  198. [198]
    Musk's Neuralink says 12 people have received its implants - Reuters
    Sep 9, 2025 · Neuralink began human trials in 2024 on its brain implant after addressing safety concerns raised by the U.S. Food and Drug Administration ...
  199. [199]
    What to expect from Neuralink in 2025 - MIT Technology Review
    Jan 16, 2025 · Considering these two studies only, Neuralink would carry out at least two more implants by the end of 2025 and eight by the end of 2026.
  200. [200]
    Brain-controlled bionic limbs are inching closer to reality
    Oct 3, 2024 · A recent trial tested one new integration technique, which involves surgically reconstructing muscle pairs that give recipients a sense of the position and ...Missing: 2020s | Show results with:2020s
  201. [201]
    Advances in AI-based prosthetics development: editorial - PMC - NIH
    The development of prosthetics has progressed from the 'hook for a hand' to 'robotic limbs', which are able to receive neurological signals from the brain's ...Missing: 2020s | Show results with:2020s
  202. [202]
    Inside the scientific quest to reverse human aging
    Mar 6, 2025 · Can reprogramming our genes make us young again? A breakthrough in longevity research may be nearing its first human trials. March 6, 2025.Missing: 2020s | Show results with:2020s
  203. [203]
    Human trials exploring anti-aging medicines - ScienceDirect
    Feb 6, 2024 · Similar to metformin, rapamycin and rapalogs have the benefit of inhibiting release of SASP factors by senescent cells.,. Spermidine ...
  204. [204]
    Focus on Cognitive Enhancement: A Narrative Overview of ...
    Sep 11, 2025 · Overall, nootropics are thought to improve brain function without directly releasing neurotransmitters or binding to receptors. Indeed, they ...Missing: empirical peer
  205. [205]
    Cognitive enhancing drugs: Scientific and legal perspectives
    Aug 29, 2025 · These drugs have been shown to improve cognitive performance in people without a diagnosis with generally small to moderate effects. In addition ...Missing: 2020s | Show results with:2020s
  206. [206]
    If Ray Kurzweil Is Right (Again), You'll Meet His Immortal Soul in the ...
    Jun 13, 2024 · The famed futurist remains inhumanly optimistic about the world and his own fate—and thinks the singularity is minutes away.
  207. [207]
    [PDF] The Singularity and Human Destiny
    Author and inventor Ray Kurzweil sees a radical evolution of the human species in the next 40 years. We stand on the threshold of the most profound and ...
  208. [208]
    The Future of Humanity - Nick Bostrom
    A discussion about the future of humanity is about how the important fundamental features of the human condition may change or remain constant in the long run.
  209. [209]
    Genetic enhancement, human extinction, and the best interests of ...
    Sep 22, 2022 · The cumulative impact of enhancement technologies may alter the human species in the very long-term future. In this article, I will start ...
  210. [210]
    [PDF] Existential Risks: Analyzing Human Extinction Scenarios and ...
    In addition to well-known threats such as nuclear holocaust, the prospects of radically transforming technologies like nanotech systems and machine intelligence ...
  211. [211]
    Human Genetic Enhancements - A Transhumanist Perspective
    An analysis of the ethics of genetically enhancing humans. Discusses inequality, reversibility, and changing human nature.
  212. [212]
    On the (Non-)Rationality of Human Enhancement and Transhumanism
    Nov 1, 2022 · Human Enhancement (HE) and Transhumanism. The core idea of human enhancement is the prospect of improving or human abilities, performance, or ...
  213. [213]
    Could ChatGPT Be a Cognitive Prosthesis?
    Examines AI chatbots functioning as cognitive prostheses for memory and planning support, with associated psychological risks.
  214. [214]
    The algorithmic self: how AI is reshaping human identity, introspection, and agency
    Discusses AI's role in reshaping human agency, identity, and social assignment of responsibility.
  215. [215]
    From Lived Experience to Insight: Unpacking the Psychological Risks of Using AI Conversational Agents
    Analyzes psychological harms to identity and agency from AI conversational agents.